<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy - Rolim, LCSP - 2019 | Cochrane Library</title> <meta content="Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy - Rolim, LCSP - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011265.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy - Rolim, LCSP - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011265.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011265.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy" name="citation_title"/> <meta content="Luiz CSP Rolim" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Edina MK da Silva" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Ronald LG Flumignan" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="flumignan@gmail.com" name="citation_author_email"/> <meta content="Marcio M Abreu" name="citation_author"/> <meta content="Yale University School of Medicine" name="citation_author_institution"/> <meta content="Sérgio A Dib" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD011265.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/06/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011265.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011265.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011265.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetylcarnitine [administration &amp; dosage, adverse effects, *therapeutic use]; Diabetes Mellitus, Type 1 [*complications]; Diabetes Mellitus, Type 2 [*complications]; Diabetic Neuropathies [complications, *drug therapy]; Neuralgia [*drug therapy]; Pain Measurement; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Sensation [drug effects]; Vibration; Vitamin B 12 [administration &amp; dosage, analogs &amp; derivatives, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011265.pub2&amp;doi=10.1002/14651858.CD011265.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011265\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011265\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","ja","fr","pl","pt","hr","fa","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011265.pub2",title:"Acetyl\\u2010L\\u2010carnitine for the treatment of diabetic peripheral neuropathy",firstPublishedDate:"Jun 15, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011265.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011265.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011265.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011265.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011265.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011265.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011265.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011265.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011265.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011265.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7462 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011265.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-sec-0123"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-sec-0049"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-sec-0050"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-sec-0078"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-sec-0117"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/appendices#CD011265-sec-0128"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/table_n/CD011265StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/table_n/CD011265StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/information#CD011265-cr-0002">Luiz CSP Rolim</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/information#CD011265-cr-0003">Edina MK da Silva</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/information#CD011265-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ronald LG Flumignan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/information#CD011265-cr-0005">Marcio M Abreu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011265.pub2/information#CD011265-cr-0006">Sérgio A Dib</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/information/en#CD011265-sec-0137">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 June 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011265.pub2">https://doi.org/10.1002/14651858.CD011265.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011265-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011265-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011265-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011265-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011265-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011265-abs-0013">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011265-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011265-abs-0001" lang="en"> <section id="CD011265-sec-0001"> <h3 class="title" id="CD011265-sec-0001">Background</h3> <p>Diabetic peripheral neuropathy (DPN) is a common and severe complication that affects 50% of people with diabetes. Painful DPN is reported to occur in 16% to 24% of people with diabetes. A complete and comprehensive management strategy for the prevention and treatment of DPN, whether painful or not, has not yet been defined. </p> <p>Research into treatment for DPN has been characterised by a series of failed clinical trials, with few noteworthy advances. Strategies that support peripheral nerve regeneration and restore neurological function in people with painful or painless DPN are needed. The amino acid acetyl‐L‐carnitine (ALC) plays a role in the transfer of long‐chain fatty acids into mitochondria for β‐oxidation. ALC supplementation also induces neuroprotective and neurotrophic effects in the peripheral nervous system. Therefore, ALC supplementation targets several mechanisms relevant to potential nerve repair and regeneration, and could have clinical therapeutic potential. There is a need for a systematic review of the evidence from clinical trials. </p> </section> <section id="CD011265-sec-0002"> <h3 class="title" id="CD011265-sec-0002">Objectives</h3> <p>To assess the effects of ALC for the treatment of DPN.</p> </section> <section id="CD011265-sec-0003"> <h3 class="title" id="CD011265-sec-0003">Search methods</h3> <p>On 2 July 2018, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform. We checked references, searched citations, and contacted study authors to identify additional studies. </p> </section> <section id="CD011265-sec-0004"> <h3 class="title" id="CD011265-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs of ALC compared with placebo, other therapy, or no intervention in the treatment of DPN. Participants could be of any sex and age, and have type 1 or type 2 diabetes mellitus, of any severity, with painful or painless DPN. We accepted any definition of minimum criteria for DPN, in accordance with the Toronto Consensus. We imposed no language restriction. </p> <p>Pain was the primary outcome, measured as the proportion of participants with at least 30% (moderate) or 50% (substantial) decrease in pain over baseline, or as the score on a visual analogue scale (VAS) or Likert scale for pain. </p> </section> <section id="CD011265-sec-0005"> <h3 class="title" id="CD011265-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methods.</p> </section> <section id="CD011265-sec-0006"> <h3 class="title" id="CD011265-sec-0006">Main results</h3> <p>We included four studies with 907 participants, which were reported in three publications. Three trials studied ALC versus placebo (675 participants); in one trial the dose of ALC was 2000 mg/day, and in the other two trials, it was 1500 mg/day or 3000 mg/day. The fourth trial studied ALC 1500 mg/day versus methylcobalamin 1.5 mg/day (232 participants). The risk of bias was high in both trials of different ALC doses and low in the other two trials. </p> <p>No included trial measured the proportion of participants with at least moderate (30%) or substantial (50%) pain relief. ALC reduced pain more than placebo, measured on a 0‐ to 100‐mm VAS (MD ‐9.16, 95% CI ‐16.76 to ‐1.57; three studies; 540 participants; P = 0.02; I² = 56%; random‐effects; very low‐certainty evidence; a higher score indicating more pain). At doses of 1500 mg/day or less, the VAS score after ALC treatment was little different from placebo (MD ‐0.05, 95% CI ‐10.00 to 9.89; two studies; 159 participants; P = 0.99; I² = 0%), but at doses greater than 1500 mg/day, ALC reduced pain more than placebo (MD ‐14.93, 95% CI ‐19.16 to ‐10.70; three studies; 381 participants; P &lt; 0.00001; I² = 0%). This subgroup analysis should be viewed with caution as the evidence was even less certain than the overall analysis, which was already of very low certainty. </p> <p>Two placebo‐controlled studies reported that vibration perception improved after 12 months. We graded this evidence as very low certainty, due to inconsistency and a high risk of bias, as the trial authors did not provide any numerical data. The placebo‐controlled studies did not measure functional impairment and disability scores. No study used validated symptom scales. One study performed sensory testing, but the evidence was very uncertain. </p> <p>The fourth included study compared ALC with methylcobalamin, but did not report effects on pain. There was a reduction from baseline to 24 weeks in functional impairment and disability, based on the change in mean Neuropathy Disability Score (NDS; scale from zero to 10), but there was no important difference between the ALC group (mean score 1.66 ± 1.90) and the methylcobalamin group (mean score 1.35 ± 1.65) groups (P = 0.23; low‐certainty evidence). </p> <p>One placebo‐controlled study reported that six of 147 participants in the ALC &gt; 1500 mg/day group (4.1%) and two of 147 participants in the placebo group (1.4%) discontinued treatment because of adverse events (headache, facial paraesthesia, and gastrointestinal disorders) (P = 0.17). The other two placebo‐controlled studies reported no dropouts due to adverse events, and more pain, paraesthesia, and hyperaesthesias in the placebo group than the 3000 mg/day ALC group, but provided no numerical data. The overall certainty of adverse event evidence for the comparison of ALC versus placebo was low. </p> <p>The study comparing ALC with methylcobalamin reported that 34/117 participants (29.1%) experienced adverse events in the ALC group versus 33/115 (28.7%) in the methylcobalamin group (P = 0.95). Nine participants discontinued treatment due to adverse events (ALC: 4 participants, methylcobalamin: 5 participants), which were most commonly gastrointestinal symptoms. The certainty of the adverse event evidence for ALC versus methylcobalamin was low. </p> <p>Two studies were funded by the manufacturer of ALC and the other two studies had at least one co‐author who was a consultant for an ALC manufacturer. </p> </section> <section id="CD011265-sec-0007"> <h3 class="title" id="CD011265-sec-0007">Authors' conclusions</h3> <p>We are very uncertain whether ALC causes a reduction in pain after 6 to 12 months' treatment in people with DPN, when compared with placebo, as the evidence is sparse and of low certainty. Data on functional and sensory impairment and symptoms are lacking, or of very low certainty. The evidence on adverse events is too uncertain to make any judgements on safety. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011265-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011265-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011265-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011265-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011265-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011265-abs-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011265-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011265-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011265-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011265-abs-0014">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011265-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011265-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011265-abs-0018">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011265-abs-0005" lang="en"> <h3>Acetyl‐L‐carnitine for the treatment of diabetic neuropathy</h3> <p><b>The aim of this review</b> </p> <p>The aim of this review was to assess the effects of acetyl‐L‐carnitine (ALC) on diabetic peripheral neuropathy (DPN) in people with diabetes. We were particularly interested in whether ALC could relieve pain, and also aimed to identify any harmful effects. </p> <p><b>Key messages</b> </p> <p>We are uncertain whether ALC reduces pain in DPN, as the evidence is sparse and of very low certainty. Adverse events may be no more common than with placebo, but the evidence here is also very uncertain. </p> <p><b>What was studied in the review?</b> </p> <p>Diabetes is a condition where the amount of sugar in the blood is abnormally high. Damage to nerve fibres as a result of diabetes is called DPN. DPN is a frequent and severe complication of diabetes, affecting about 50% of people with long‐term diabetes. Overall, 16% to 24% of people with diabetes experience chronic pain due to nerve damage. The feet, legs, and hands are primarily affected by DPN. </p> <p>There is a need for therapies to restore nerve function and relieve the symptoms of DPN. The Cochrane review authors searched for evidence from randomised trials on the effects of ALC in DPN. Evidence from randomised trials is usually more reliable than other study designs. </p> <p><b>The main results of the review</b> </p> <p>The review authors found four relevant trials, which involved 906 adults with diabetes. Three studies compared ALC with a placebo (an inactive, dummy compound), and one compared ALC with methylcobalamin (a form of vitamin B<sub>12</sub>). </p> <p>The certainty of the evidence from the studies ranged from low to very low, which means that we cannot be confident in the findings. The key reasons for this were that results were not always completely or clearly reported, the studies had serious limitations, and the results lacked precision. </p> <p>In people with nerve damage due to diabetes, it is uncertain whether ALC reduces pain after 12 months of therapy, compared to placebo. The trials provided little or no information on the effects of ALC on functional impairment, sensory testing, and symptoms. Even when trials provided data, the quality of evidence was too low to draw reliable conclusions. The study that compared ALC with methylcobalamin did not assess pain. Functional impairment and symptoms may improve to a similar extent with ALC and methylcobalamin. </p> <p>Harmful side effects may be no more frequent with ALC than with placebo. The evidence on adverse events from the trial comparing ALC with methylcobalamin was very uncertain. </p> <p>Two of the four studies were funded by a manufacturer of ALC and the other two studies had at least one co‐author who was a consultant for an ALC manufacturer. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011265-sec-0123" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011265-sec-0123"></div> <h3 class="title" id="CD011265-sec-0124">Implications for practice</h3> <section id="CD011265-sec-0124"> <p>It is uncertain whether, in comparison with placebo, acetyl‐L‐carnitine (ALC) reduces pain in people with diabetic peripheral neuropathy (DPN) after 6 to 12 months; any effect may be present at doses greater than 1500 mg/day but not at lower doses. Data on functional and sensory impairment and symptoms are lacking, or the evidence is of very low certainty. The evidence on adverse events is too uncertain to make any judgements on safety. </p> </section> <h3 class="title" id="CD011265-sec-0125">Implications for research</h3> <section id="CD011265-sec-0125"> <p>The use of ALC for DPN is primarily an attempt to improve poor neurological function due to the metabolic effects of diabetes, and thereby reduce chronic pain. Since pain control is the most relevant outcome for people with diabetes and their clinicians, it is important that future studies of DPN measure pain as a primary outcome, preferably as the proportion of participants with at least moderate (30%) or substantial (50%) pain relief. Future trials need to be large enough to detect effects on clinical outcomes; they should include not only the main clinical outcome of pain, but also measure impairment or disability, sensory function, and symptoms, and use validated scales. Finally, studies need to be of at least two years' duration to assess the long‐term effects of ALC. Even though a two‐year follow‐up is arbitrary, it may be long enough to provide additional data on rare adverse events following ALC treatment, and assess its effects on chronic morbidity. Future trials should include participants with type 1 and type 2 diabetes, and provide individual data by type of diabetes. Continuous outcome data need to be uniform, with use of similar scales, especially for pain and quality of life. </p> <p>Further studies, with the characteristics suggested above, comparing ALC with a placebo control, remain necessary to evaluate ALC for wider clinical use. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011265-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011265-sec-0043"></div> <div class="table" id="CD011265-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Acetyl‐L‐carnitine compared to placebo for the treatment of diabetic polyneuropathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Acetyl‐L‐carnitine compared to placebo for the treatment of diabetic peripheral neuropathy (DPN)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic peripheral neuropathy<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> acetyl‐L‐carnitine (ALC; 1500 mg/day to 3000 mg/day)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Acetyl‐L‐carnitine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> at 6 months or more; all doses </p> <p>Assessed by change from baseline, using a 0‐ to 100‐mm VAS, where higher scores indicate more pain) </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The control group baseline average VAS score was 49.2<sup>a</sup> </p> <p>The average improvement in the control groups was 10.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS pain score improved on average 9.16 points more (1.57 to 16.76 points more) than in the placebo group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>540<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b,c,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional impairment and disability</b> </p> <p>Assessed by NIS or NDS at 6 months or more</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Included studies did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Impairment of sensation</b> </p> <p>Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The group that received ALC 3000 mg/day had better vibration perception than the placebo group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> <p>2 RCTs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>d,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 2 RCTs that measured this outcome did not provide complete data. Not measured in a 3rd trial </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Impairment of sensation</b> </p> <p>Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Included studies did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptom quality and severity</b> </p> <p>Assessed by change in symptom score on a validated screening questionnaire (NSS or MNSI) at 6 months or more </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Although 2 other studies assessed symptoms, the scale used was not validated. A 3rd study did not assess symptom quality and severity. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b>: any adverse event, adverse events requiring withdrawal, and serious adverse events </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study found no clear difference in withdrawals in the intervention group (4.1%) compared with the placebo group (1.4%, P = 0.17). </p> <p>1 study reported no dropouts due to adverse events, and less pain (P = 0.026), paraesthesia (P = 0.023), and hyperaesthesias (P = 0.025) in the 3000 mg/day ALC group than the placebo group. </p> <p>1 study provided no numerical data.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>540<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ALC</b> : acetyl‐L‐carnitine; <b>CI</b> : confidence interval; <b>MNSI</b> : Michigan Neuropathy Screening Instrument; <b>NDS</b> : Neuropathy Disability Score; <b>NIS</b> : Neuropathy Impairment Score; <b>NSS</b> : Neuropathy Symptom Score; <b>RCT</b> : randomised controlled trial; <b>VAS</b>: visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Mean baseline scores from included studies (score estimated from a graph in <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>).<br/> <sup>b</sup>Downgraded one level for indirectness: the outcome is indirectly related to the function of the intervention (ALC does not have a direct effect on pain relief), and we were unable to report the outcome as specified (i.e. the number with 30% pain relief).<br/> <sup>c</sup>Downgraded one level due to imprecision: the CI included the possibility of both a clinically important effect and little or no effect.<br/> <sup>d</sup>Downgraded one level for study limitations, due to an unclear risk of bias in three included studies in several domains. <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>, and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> did not fully describe methods of randomisation, allocation concealment, or blinding. <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a> was at an unclear risk of bias from attrition and blinding of outcome assessors. We also assessed the selection of participants for measurement of pain at unclear risk of bias.<br/> <sup>e</sup>Heterogeneity in the pain analysis was substantial (I² = 56% and differences between participants). This might be explained by differences in effect between ALC ≤ 1500 mg/day and &gt; 1500 mg/day subgroups.<br/> <sup>f</sup>Downgraded two levels: in the absence of numerical data, the outcome was at high risk of reporting bias, and precision could not be assessed. The two trials were not reported separately and we do not know if the results were consistent. We must therefore be very uncertain about the estimate.<br/> <sup>g</sup>Downgraded one level for reporting bias, as one trial did not provide data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011265-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Acetyl‐L‐carnitine compared to methylcobalamin for the treatment of diabetic polyneuropathy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Acetyl‐L‐carnitine compared to methylcobalamin for the treatment of diabetic peripheral neuropathy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> the treatment of diabetic peripheral neuropathy<br/> <b>Setting:</b> outpatients, China<br/> <b>Intervention:</b> acetyl‐L‐carnitine (ALC, ≤ 1500 mg/day)<br/> <b>Comparison:</b> methylcobalamin (0.5 mg three times per day) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with methylcobalamin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with acetyl‐L‐carnitine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain</b> at 6 months or more </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional impairment and disability</b> </p> <p>Assessed by change in NDS score (range of possible scores from 0 (normal function) to 10 (maximal disability) </p> <p>Follow‐up: 24 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The methylcobalamin group baseline average NDS score was 6.43.</p> <p>The average improvement in the methylcobalamin group was 1.35 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The average NDS score improved 0.31 more in the ALC group than in the methylcobalamin group (0.15 less to 0.77 more). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Impairment of sensation</b>: quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Impairment of sensation</b>: quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptom quality and severity</b> </p> <p>Assessed by NSS score (range of possible scores 0 to 9; higher scores indicate more symptoms) </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The methylcobalamin group baseline average NSS score was 6.37</p> <p>The average change (decrease) in the methylcobalamin group was 2.11 points.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The average NSS score improved 0.24 more<br/> in the ALC group than in the methylcobalamin group (0.37 less to 0.85 more). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>287 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000<br/> (195 to 436) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.68 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>ALC</b> : Acetyl‐L‐carnitine; <b>CI</b> : confidence interval; <b>NDS</b> : Neuropathy Disability Score; <b>NIS</b> : Neuropathy Impairment Score; <b>NSS</b> : Neuropathy Symptom Score; <b>RCT</b> : randomised controlled trial; <b>VAS</b>: visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for indirectness, as the control intervention methylcobalamin is not an established treatment for DPN and its effects are uncertain.<br/> <sup>b</sup>Downgraded once for imprecision: the CI included the possibility of both a clinically important effect and little or no effect; small sample (232 participants).<br/> <sup>c</sup>Downgraded once for indirectness, as the comparator made it difficult to distinguish the adverse effects of ALC. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011265-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011265-sec-0044"></div> <section id="CD011265-sec-0045"> <h3 class="title" id="CD011265-sec-0045">Description of the condition</h3> <p>Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes mellitus, affecting approximately 50% of people with diabetes (<a href="./references#CD011265-bbs2-0036" title="TesfayeS , BoultonAJ , DyckPJ , FreemanR , HorowitzM , KemplerP , et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care2010;33(10):2285‐93. ">Tesfaye 2010</a>). The internationally accepted definition of DPN used in clinical practice is "the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes, after the exclusion of other causes" (<a href="./references#CD011265-bbs2-0008" title="BoultonAJ , VinikAI , ArezzoJC , BrilV , FeldmanEL , FreemanR , et al. American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care2005;28(4):956‐62. ">Boulton 2005a</a>). </p> <p>DPN is frequently asymptomatic but it may be clinically evident through a set of positive and negative symptoms. The positive symptoms are often painful and the negative are abnormalities associated with lack of sensation or, less commonly, with weakness. Chronic neuropathic pain, depression, balance disorders, foot ulceration, Charcot's arthropathy, osteomyelitis, and amputations are some examples of complications associated with progressively advanced stages of DPN (<a href="./references#CD011265-bbs2-0012" title="CallaghanBC , LittleAA , FeldmanEL , HughesRAC . Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD007543.pub2] ">Callaghan 2012</a>). </p> <p>A combination of neuropathic symptoms, signs, and abnormal electrical diagnostic studies provides researchers with the most accurate diagnosis of peripheral neuropathy (<a href="./references#CD011265-bbs2-0020" title="EnglandJD , GronsethGS , FranklinG , MillerRG , AsburyAK , CarterGT , et al. American Academy ofNeurology , American Association of Electrodiagnostic Medicine, American Academy of PhysicalMedicine , Rehabilitation . Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology2005;64(2):199‐207. ">England 2005</a>; <a href="./references#CD011265-bbs2-0036" title="TesfayeS , BoultonAJ , DyckPJ , FreemanR , HorowitzM , KemplerP , et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care2010;33(10):2285‐93. ">Tesfaye 2010</a>). However, in clinical practice, the diagnosis of DPN is made after a careful clinical examination, with at least two neurological tests. For example, the combination of abnormal temperature and vibration tests on neurological examination of a person with diabetes has 87% sensitivity in detecting DPN (<a href="./references#CD011265-bbs2-0008" title="BoultonAJ , VinikAI , ArezzoJC , BrilV , FeldmanEL , FreemanR , et al. American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care2005;28(4):956‐62. ">Boulton 2005a</a>). </p> <p>In painful DPN, the pain is typically distal, symmetrical, and worsens at night. There are five different phenotypes of pain in DPN: (1) evoked pain (allodynia or hyperalgesia); (2) paroxysmal pain (electric shock, sharp); (3) deep pain (compression, tightness); (4) superficial pain (burning); and (5) paraesthesia and dysaesthesia (tingling, brushing) (<a href="./references#CD011265-bbs2-0031" title="RolimLC , Koga da SilvaEM , DeSaJR , DibSA . A systematic review of treatment of painful diabetic neuropathy by pain phenotype versus treatment based on medical comorbidities. Frontiers in Neurology2017;8:285. [PUBMED: 28676788] ">Rolim 2017</a>). On examination, it is possible to observe hyperalgesia (abnormal sensitivity to painful stimuli) and allodynia (heightened sensitivity to non‐noxious stimuli), as well as hypoalgesia. The prevalence of neuropathic pain is difficult to ascertain, as definitions vary enormously among studies. It is thought that between 16% and 24% of people with DPN may experience chronic neuropathic pain (<a href="./references#CD011265-bbs2-0010" title="BoultonAJM . NICE guidelines for the management of painful diabetic neuropathy. Practical Diabetes International2010; Vol. 27, issue 6:215‐6. [DOI: 10.1002/pdi.1486] ">Boulton 2010</a>). In clinical trials, the severity of pain is evaluated through pain scales (visual analogue scale (VAS) and 11‐point Likert scale), and outcomes must be evaluated through validated instruments (for example, the Brief Pain Inventory, McGill Pain Questionnaire, or the Quality of Life in Neurological Disorders assessment tool) (<a href="./references#CD011265-bbs2-0014" title="CruccuG , AnandP , AttalN , Garcia‐LarreaL , HaanpëäM , JørumE , et al. EFNS guidelines on neuropathic pain assessment. European Journal of Neurology2004;11(3):153‐62. ">Cruccu 2004</a>). The usual criteria for including a person with DPN in a trial of painful diabetic neuropathy are the presence of DPN associated with neuropathic pain lasting for three months or longer, and a mean weekly pain level between 40 and 100, measured on a 0‐ to 100‐mm VAS. </p> <p>A long period of hyperglycaemia, metabolic imbalances such as oxidative stress, mitochondrial dysfunction, neuroinflammation, accumulation of advanced glycation end‐products, and dyslipidaemia (an increase in low density lipoprotein (LDL) and triglycerides, and a decrease in high density lipoprotein (HDL)) are the main factors associated with the development of DPN. However, overall hyperglycaemic exposure seems to be the most important factor associated with DPN (<a href="./references#CD011265-bbs2-0036" title="TesfayeS , BoultonAJ , DyckPJ , FreemanR , HorowitzM , KemplerP , et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care2010;33(10):2285‐93. ">Tesfaye 2010</a>). The elucidation of metabolic disruptions related to hyperglycaemia remains the foremost target for research, with the aim of reversing or minimising these homeostatic imbalances, and eventually reducing complications and negative impacts on quality of life in persons with DPN. </p> <p>Apart from tight blood glucose control in type 1 diabetes mellitus, no treatments have shown any capacity to arrest DPN progression. In addition, the pharmacological treatment of painful DPN remains a challenge for physicians, and the ability of the individual to tolerate treatment remains a major consideration in any treatment decision (<a href="./references#CD011265-bbs2-0043" title="ZieglerD . Painful diabetic neuropathy: advantage of novel drugs over old drugs?. Diabetes Care2009;32(Suppl 2):S414‐9. ">Ziegler 2009</a>). A multifaceted treatment approach to chronic neuropathic pain in DPN is reasonable but results, even in the best RCTs, have been modest so far (<a href="./references#CD011265-bbs2-0031" title="RolimLC , Koga da SilvaEM , DeSaJR , DibSA . A systematic review of treatment of painful diabetic neuropathy by pain phenotype versus treatment based on medical comorbidities. Frontiers in Neurology2017;8:285. [PUBMED: 28676788] ">Rolim 2017</a>). Currently, there are many treatments for painful DPN, but adverse effects can limit their utility (<a href="./references#CD011265-bbs2-0011" title="BrilV , EnglandJ , FranklinGM , BackonjaM , CohenJ , DelToroD , et al. American Academy ofNeurology , American Association of Neuromuscular and Electrodiagnostic Medicine, American Academy of PhysicalMedicine , Rehabilitation . Evidence‐based guideline. Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology2011;76(20):1758‐65. [DOI: 10.1212/WNL.0b013e3182166ebe] ">Bril 2011</a>), and very few papers have studied the effects of treatment on function and quality of life. </p> </section> <section id="CD011265-sec-0046"> <h3 class="title" id="CD011265-sec-0046">Description of the intervention</h3> <p>Acetyl‐L‐carnitine is a naturally occurring amino acid that is sometimes used as a dietary supplement. In humans, the metabolic pool of carnitine comprises nonesterified levo‐carnitine (L‐carnitine) and acyl carnitine esters. Of these, acetyl‐L‐carnitine (ALC) forms the greatest component. Three mechanisms control carnitine homeostasis: absorption from diet, a limited rate of synthesis, and effective renal reabsorption (<a href="./references#CD011265-bbs2-0028" title="ReboucheCJ . Kinetics, pharmacokinetics, and regulation of L‐carnitine and acetyl‐L‐carnitine metabolism. Annals of the New York Academy of Sciences2004;1033:30‐41. [PUBMED: 15591001] ">Rebouche 2004</a>). ALC is produced in the kidneys, central nervous system and liver, via the action of ALC‐transferase, and is stored in skeletal muscle. ALC plays an essential role in the transfer of long‐chain fatty acids into the mitochondria for β‐oxidation (<a href="./references#CD011265-bbs2-0035" title="SimaAA . Acetyl‐L‐carnitine in diabetic polyneuropathy: experimental and clinical data. CNS Drugs2007;21(Suppl 1):13‐23. ">Sima 2007</a>). ALC supports cell metabolism during hypoxia from, for example, reduced circulation, or due to genetic metabolic defects. Binding of organic acids and fragmented free fatty acids by ALC enables their expulsion from the cell and prevents them from harming cell and tissue structures. </p> <p>In addition, ALC is able to reduce the concentration of tumour necrosis factor alpha, and has an antioxidant effect on mitochondrial DNA, whilst stimulating mitochondrial DNA synthesis. Therefore, ALC not only assists in the transportation of long‐chain fatty acids through the inner mitochondrial membrane for β‐oxidation, but also has a role in energy availability and prevents toxic accumulation of long‐chain fatty acids (<a href="./references#CD011265-bbs2-0040" title="WilliamsonJR , Arrigoni‐MarteliE . The roles of glucose‐induced metabolic hypoxia and imbalances in carnitine metabolism in mediating diabetes‐induced vascular dysfunction. International Journal of Clinical Pharmacology Research1992;12(5‐6):247‐52. ">Williamson 1992</a>). </p> <p>ALC can be administered orally, intravenously, or intramuscularly. Oral doses range from 1500 mg to 3000 mg per day, in divided doses. Intravenous and intramuscular doses range from 1000 mg to 2000 mg daily. These doses result in physiologically meaningful blood levels (<a href="./references#CD011265-bbs2-0007" title="Acetyl‐L‐carnitine. Monograph. Alternative Medicine Review2010;15(1):76‐83. [PUBMED: 20359271] ">Anon 2010</a>). </p> </section> <section id="CD011265-sec-0047"> <h3 class="title" id="CD011265-sec-0047">How the intervention might work</h3> <p>Clinical trials, usually in people with an advanced stage of DPN, have shown disappointing outcomes from experimental treatments based on vitamin supplementation, aldose reductase inhibitors, and protein kinase C inhibitors (<a href="./references#CD011265-bbs2-0010" title="BoultonAJM . NICE guidelines for the management of painful diabetic neuropathy. Practical Diabetes International2010; Vol. 27, issue 6:215‐6. [DOI: 10.1002/pdi.1486] ">Boulton 2010</a>; <a href="./references#CD011265-bbs2-0041" title="WongMC , ChungJW , WongTK . Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ (Clinical research ed.)2007;335(7610):87. [PUBMED: 17562735] ">Wong 2007</a>). In these studies, each drug has targeted a single underlying pathogenic factor. By contrast, ALC potentially targets several mechanisms to reduce disease progression (<a href="./references#CD011265-bbs2-0035" title="SimaAA . Acetyl‐L‐carnitine in diabetic polyneuropathy: experimental and clinical data. CNS Drugs2007;21(Suppl 1):13‐23. ">Sima 2007</a>). </p> <p>In experimental diabetic neuropathy, as well as in human diabetic neuropathy, ALC is depleted in peripheral nerves (<a href="./references#CD011265-bbs2-0032" title="ScarpiniE , DonedaP , PizzulS , ChiodiP , RamacciMT , BaronP , et al. L‐carnitine and acetyl‐L‐carnitine in human nerves from normal and diabetic subjects. Journal of the Peripheral Nervous System1996;1(2):157‐63. ">Scarpini 1996</a>). Replenishment of ALC enhances regional blood flow, increases myo‐inositol and free carnitine levels, and reduces malonyl dialdehyde (that is, reduces lipid peroxidation). </p> </section> <section id="CD011265-sec-0048"> <h3 class="title" id="CD011265-sec-0048">Why it is important to do this review</h3> <p>Peripheral neuropathy is a frequent, polymorphic, and devastating complication associated with diabetes mellitus, characterised by debilitating symptoms. In addition, it is associated with an increased risk of other complications, in particular, those involving the cardiovascular system and the foot (<a href="./references#CD011265-bbs2-0030" title="RolimLC , SáJR , ChacraAR , DibSA . Clinical heterogeneity and coexistence of diabetic neuropathies: difference and similarities between types 1 and 2 diabetes mellitus [Heterogeneidade Clínica e Coexistência da Neuropatias Diabéticas: Diferenças e Semelhanças entre Diabetes Melito Tipos 1 e 2]. Arquivos Brasileiro Endocrinologia e Metabologia2009;53(7):818‐24. ">Rolim 2009</a>). The World Health Organization (WHO) estimates that "every 30 seconds a lower limb is lost somewhere in the world as a consequence of diabetes" (<a href="./references#CD011265-bbs2-0009" title="BoultonAJM , VileikyteL , Ragnarson‐TennvallG , ApelqvisJ . The global burden of diabetic foot disease. Lancet2005;366:1719‐24. ">Boulton 2005b</a>). </p> <p>There are over 415 million adults with diabetes in the world. Of these, approximately half have DPN, and 16% to 24% have chronic painful DPN (<a href="./references#CD011265-bbs2-0010" title="BoultonAJM . NICE guidelines for the management of painful diabetic neuropathy. Practical Diabetes International2010; Vol. 27, issue 6:215‐6. [DOI: 10.1002/pdi.1486] ">Boulton 2010</a>). Of those with chronic painful DPN, up to 39% have never received any kind of treatment for their pain (<a href="./references#CD011265-bbs2-0015" title="DaousiC , MacFarlaneIA , WoodwardA , NurmikkoTJ , BundredPE , BenbowSJ . Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabetic Medicine2004;21(9):976‐82. ">Daousi 2004</a>). Other than excellent diabetic control, there are no known modulators of neuropathy occurrence or progression. Therefore, there is a substantial worldwide burden of disease, and an unmet need for prevention and treatment of DPN and its complications, including chronic neuropathic pain, the diabetic foot, and amputation. </p> <p>At least four systematic reviews and meta‐analyses have been published about ALC or L‐carnitine and their effects on different conditions: type 2 diabetes mellitus (<a href="./references#CD011265-bbs2-0038" title="Vidal‐CasariegoA , Burgos‐PeláezR , Martínez‐FaedoC , Calvo‐GraciaF , Valero‐ZanuyMÁ , Luengo‐PérezLM , et al. Metabolic effects of L‐carnitine on type 2 diabetes mellitus: systematic review and meta‐analysis. Experimental and Clinical Endocrinology &amp; Diabetes2013;121(4):234‐8. ">Vidal‐Casariego 2013</a>), secondary prevention of cardiovascular disease (<a href="./references#CD011265-bbs2-0017" title="DiNicolantonioJJ , LavieCJ , FaresH , MenezesAR , O'KeefeJH . L‐carnitine in the secondary prevention of cardiovascular disease: systematic review and meta‐analysis. Mayo Clinic Proceedings2013;88(6):544‐51. ">DiNicolantonio 2013</a>), hepatic encephalopathy (<a href="./references#CD011265-bbs2-0025" title="JiangQ , JiangG , ShiKQ , CaiH , WangYX , ZhengMH . Oral acetyl‐L‐carnitine treatment in hepatic encephalopathy: view of evidence‐based medicine. Annals of Hepatolology2013;12(5):803‐9. ">Jiang 2013</a>), end‐stage renal failure under haemodialysis (<a href="./references#CD011265-bbs2-0013" title="ChenY , AbbateM , TangL , CaiG , GongZ , WeiR , et al. L‐carnitine supplementation for adults with end‐stage kidney disease requiring maintenance haemodialysis: a systematic review and meta‐analysis. American Journal of Clinical Nutrition2014;99(2):408‐22. ">Chen 2014</a>), with positive results in all except renal failure. ALC has been reported to show promise as a therapeutic agent for DPN in a small number of studies and reviews (<a href="./references#CD011265-bbs2-0026" title="LiS , LiQ , LiY , LiL , TianH , SunX . Acetyl‐L‐carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta‐analysis of randomized controlled trials. PloS One2015;10(3):e0119479. [PUBMED: 25751285] ">Li 2015</a>; <a href="./references#CD011265-bbs2-0037" title="VeroneseN , SergiG , StubbsB , Bourdel‐MarchassonI , TessierD , SieberC , et al. the EUGMS special interest group on diabetes. Effect of acetyl‐l‐carnitine in the treatment of diabetic peripheral neuropathy: a systematic review and meta‐analysis. European Geriatric Medicine2017;8(2):117‐22. [DOI: 10.1016/j.eurger.2017.01.002] ">Veronese 2017</a>), but this is the first Cochrane Systematic Review of ALC for DPN. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011265-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011265-sec-0049"></div> <p>To assess the effects of acetyl‐L‐carnitine (ALC) for the treatment of diabetic peripheral neuropathy (DPN). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011265-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011265-sec-0050"></div> <section id="CD011265-sec-0051"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011265-sec-0052"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) and quasi‐RCTs with parallel or cross‐over designs.</p> <p>Quasi‐RCTs are studies in which participants are allocated to intervention groups using methods that aim to be random, but which are potentially predictable, such as assignment based on hospital number or date of birth. </p> </section> <section id="CD011265-sec-0053"> <h4 class="title">Types of participants</h4> <p>People of any sex and age (adults, including those over 60 years, and children), with either form of diabetes (type 1 or type 2). Diabetic participants could have any severity of DPN (for example, stages from Grade 0 to Grade 5 described by <a href="./references#CD011265-bbs2-0018" title="DyckPJ . Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle &amp; Nerve1988;11(1):21‐32. ">Dyck 1988</a>) and any of the three definitions of minimal criteria for typical DPN, as recommended by the Toronto Consensus (<a href="./references#CD011265-bbs2-0036" title="TesfayeS , BoultonAJ , DyckPJ , FreemanR , HorowitzM , KemplerP , et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care2010;33(10):2285‐93. ">Tesfaye 2010</a>), that is, probable, confirmed, or subclinical DPN. </p> <p>We considered that trials in participants with only symptoms or signs of DPN (i.e. with 'probable DPN') provided a lower certainty of evidence. </p> </section> <section id="CD011265-sec-0054"> <h4 class="title">Types of interventions</h4> <p>ALC compared with placebo, other treatment, or no intervention. Where additional treatments were given, these must have been matched equally in the intervention and control groups. </p> </section> <section id="CD011265-sec-0055"> <h4 class="title">Types of outcome measures</h4> <p>The outcomes listed were not eligibility criteria for the review, but were the outcomes of interest in whichever studies were included. </p> <section id="CD011265-sec-0056"> <h5 class="title">Primary outcomes</h5> <p><b>Pain</b>: measured using a validated scoring system such as a visual analogue scale (VAS) or numerical rating scale reported as the proportion of participants with at least 30% (moderate) pain relief over baseline or 50% (substantial) pain relief over baseline or as a continuous outcome on a VAS or Likert scale (<a href="./references#CD011265-bbs2-0014" title="CruccuG , AnandP , AttalN , Garcia‐LarreaL , HaanpëäM , JørumE , et al. EFNS guidelines on neuropathic pain assessment. European Journal of Neurology2004;11(3):153‐62. ">Cruccu 2004</a>). The time scale was six months (at minimum) after treatment, and, when possible, at a year or even two or more years after treatment. </p> <p>We used pain as the primary outcome measure because a significant proportion of people with diabetes have painful DPN, it causes significant ill health and disability, and many trials use pain as a surrogate measure of disease severity. </p> </section> <section id="CD011265-sec-0057"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011265-list-0001"> <li> <p><b>Functional impairment and disability</b>: assessed by change in the Neuropathy Impairment Score (NIS) (<a href="./references#CD011265-bbs2-0018" title="DyckPJ . Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle &amp; Nerve1988;11(1):21‐32. ">Dyck 1988</a>) or the Neuropathy Disability Score (NDS) (or one of the modified NDS scores) in the lower extremities (<a href="./references#CD011265-bbs2-0042" title="YoungMJ , BoultonAJ , MacLeodAF , WilliamsDRR , SonksenPH . A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia1993;36(2):150‐4. ">Young 1993</a>), at a minimum of six months after treatment. We considered these outcomes as continuous variables (for example, score on a scale of zero to 10 for the modified NDS). </p> </li> <li> <p><b>Impairment of sensation</b>: assessed by changes in quantitative sensory testing (vibration perception threshold and thermal threshold), at a minimum of six months after treatment. </p> </li> <li> <p><b>Quality of life</b>: assessed by changes in scores on a validated questionnaire, such as the 36‐item Short Form Health Survey (SF‐36) or the Quality of Life in Neurological Disorders (NeuroQol) assessment tool (<a href="./references#CD011265-bbs2-0039" title="VileikyteL , PeyrotM , BundyC , RubinRR , LeventhalH , MoraP , et al. The development and validation of a neuropathy and foot ulcer‐specific quality of life instrument. Diabetes Care2003;26(9):2549‐55. ">Vileikyte 2003</a>), at a minimum of six months after treatment. </p> </li> <li> <p><b>Neurophysiological measures</b>: assessed by changes in sural and peroneal nerve conduction velocities (NCVs) and changes in amplitude of either the sensory nerve action potential (SNAP) or the compound muscle action potential (CMAP) of the ulnar, peroneal, and tibial nerves after an appropriate duration of therapy (one year or more). </p> </li> <li> <p><b>Adverse events</b>: any adverse event, adverse events requiring withdrawal, and serious adverse events (those that are fatal, life‐threatening, or require prolonged hospitalisation). </p> </li> <li> <p><b>Symptom quality and severity</b>: assessed by changes in scores on validated screening questionnaires, such as the Neuropathy Symptom Score (NSS) or Michigan Neuropathy Screening Instrument (MNSI), at a minimum of six months after treatment. These instruments were continuous variables (e.g. from zero to 9 for NSS) (<a href="./references#CD011265-bbs2-0042" title="YoungMJ , BoultonAJ , MacLeodAF , WilliamsDRR , SonksenPH . A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia1993;36(2):150‐4. ">Young 1993</a>). </p> </li> <li> <p><b>Sural nerve biopsy parameters</b>: including quantification of axon numbers and density and of regeneration clusters. </p> </li> </ul> </p> <p>The secondary outcomes were assessed six months (at minimum) after treatment, and, when possible, at a year or even two or more years after treatment. </p> </section> </section> </section> <section id="CD011265-sec-0058"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011265-sec-0059"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases:</p> <p> <ul id="CD011265-list-0002"> <li> <p>the Cochrane Neuromuscular Specialised Register via Cochrane Register of Studies (CRS‐Web; searched 2 July 2018; <a href="./appendices#CD011265-sec-0129">Appendix 1</a>); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) via CRS‐Web (searched 2 July 2018; <a href="./appendices#CD011265-sec-0130">Appendix 2</a>); </p> </li> <li> <p>MEDLINE Ovid (1946 to 2 July 2018; <a href="./appendices#CD011265-sec-0131">Appendix 3</a>); </p> </li> <li> <p>Embase Ovid (1974 to 2 July 2018; <a href="./appendices#CD011265-sec-0132">Appendix 4</a>); </p> </li> <li> <p>LILACS iAHx (Latin American and Caribbean Health Science Information database; 1982 to 2 July 2018; <a href="./appendices#CD011265-sec-0133">Appendix 5</a>); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>; 2 July 2018; <a href="./appendices#CD011265-sec-0134">Appendix 6</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP; <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>; 2 July 2018; <a href="./appendices#CD011265-sec-0135">Appendix 7</a>). </p> </li> </ul> </p> <p>We imposed no restriction on language of publication.</p> </section> <section id="CD011265-sec-0060"> <h4 class="title">Searching other resources</h4> <p>We checked all references in the identified trials and contacted trial authors to identify any additional published or unpublished data. We checked all references in any identified review articles. </p> <p>We searched the websites of relevant manufacturers for trial information.</p> <p>We also searched for errata or retractions from included studies published in full text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>), and reported the date in such cases. </p> </section> </section> <section id="CD011265-sec-0061"> <h3 class="title" id="CD011265-sec-0061">Data collection and analysis</h3> <section id="CD011265-sec-0062"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LCSPR and EMKS) independently screened the trials identified by the literature search for inclusion in this review. They then retrieved the full‐text reports or publications of potentially eligible studies. They identified and excluded duplicates, and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. The same two review authors independently screened the full text, identified whether studies met the inclusion criteria, and identified and recorded the reasons for exclusion of ineligible studies. They consulted the other review authors (RLGF, MMA, and SAD) if there was any disagreement (at this or at any other stage listed below). In the event of disagreement, the review authors included trials only when we reached a consensus. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD011265-fig-0001">Figure 1</a>) and the '<a href="./references#CD011265-sec-0144" title="">Characteristics of excluded studies</a>' table. </p> <div class="figure" id="CD011265-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow chart illustrating the study selection process for the review." data-id="CD011265-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow chart illustrating the study selection process for the review.</p> </div> </div> </div> </section> <section id="CD011265-sec-0063"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (LCSPR and EMKS) independently extracted data. They resolved discrepancies in the results by discussion with the review team (RLGF, MMA, and SAD). They used a standard form to extract the following information: </p> <p> <ul id="CD011265-list-0003"> <li> <p>Methods: study design, total duration of study, details of any 'run in' period, number of study centres and location, study setting, withdrawals, and date of study. </p> </li> <li> <p>Participants: number, mean age, age range, gender, severity of condition, diagnostic criteria, baseline characteristics, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported, as described above. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> <li> <p>Outcome data.</p> </li> </ul> </p> <p>We collected both continuous and dichotomous data as recorded by the primary investigators. If the paper did not report outcome data in a usable way, we noted this in the '<a href="./references#CD011265-sec-0143" title="">Characteristics of included studies</a>' table. One review author (EMKS) transferred data into Review Manager 5 (<a href="./references#CD011265-bbs2-0029" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Two other review authors (LCSPR and RLGF) checked the outcome data entry. The review team (LCSPR, MMA, and SAD) spot‐checked study characteristics against the trial report for accuracy. </p> <p>If in future versions of this review reports require translation, either the translator will extract data directly using a data extraction form, or the review authors will extract data from the translation provided. After data entry, where possible, a review author will check numerical data from translated trials against the study report. </p> </section> <section id="CD011265-sec-0064"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (LCSPR and EMKS) independently assessed the risk of bias in the studies that were included in this review according to the criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011265-bbs2-0024" title="HigginsJPT , AltmanDG , Sterne JACeditor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). They resolved any conflicts by discussion with the rest of the review team (RLGF, MMA, SAD). </p> <p>Where information on risk of bias related to unpublished data or correspondence with a trial author, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that specific outcome. We followed the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> on summary 'Risk of bias' assessments (<a href="./references#CD011265-bbs2-0024" title="HigginsJPT , AltmanDG , Sterne JACeditor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). </p> <p> <ul id="CD011265-list-0004"> <li> <p>Low risk of bias: low risk of bias for all key domains.</p> </li> <li> <p>Unclear risk of bias: unclear risk of bias for one or more key domains.</p> </li> <li> <p>High risk of bias: high risk of bias for one or more key domains.</p> </li> </ul> </p> <section id="CD011265-sec-0065"> <h5 class="title">Assesment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol (<a href="./references#CD011265-bbs2-0045" title="RolimLC , daSilvaEMK , KomatsuWR , AbreuM , DibSA . Acetyl‐L‐carnitine for the treatment of diabetic polyneuropathy. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD011265; CD011265] ">Rolim 2014</a>), and reported any deviations from it in the <a href="#CD011265-sec-0141">Differences between protocol and review</a> section. </p> </section> </section> <section id="CD011265-sec-0066"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous variables, we calculated the risk ratio (RR) and 95% confidence interval (CI). For continuous outcomes, we calculated the mean difference (MD) and 95% CI when studies used the same unit of measurement for a variable. If studies measured continuous data for a variable using different instruments (different units of measurement that were not interchangeable), we would have pooled these data using the standardised mean difference (SMD). Where possible, we analysed continuous scales together. When it was not possible to combine data in this way, we dichotomised results to improvement versus no improvement or worsening, and calculated risk ratios (RRs). If the authors of the primary studies did not make the necessary information available, we planned to display any non‐parametric data (for example, effects reported with medians and quartiles) or data without sufficient statistical information (for example, missing standard deviations or numbers of participants) in an 'Additional table'. </p> </section> <section id="CD011265-sec-0067"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was based on the individual participant, that is, the number of observations in the analysis matched the number of individuals randomised. In future versions of this review, if we identify trials with a cross‐over design, we will use only first period data (the period before participants cross over to the alternative treatment) (<a href="./references#CD011265-bbs2-0019" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). </p> <p>When multiple trial arms were reported in a single trial, we included only the arms or participants relevant to the review question. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were combined in the same meta‐analysis, we halved the control group to avoid double‐counting. </p> </section> <section id="CD011265-sec-0068"> <h4 class="title">Dealing with missing data</h4> <p>Regardless of the type of data, we reported dropout rates in the `<a href="./references#CD011265-sec-0143" title="">Characteristics of included studies</a>' table, used intention‐to‐treat (ITT) analysis when possible, and specified any different analyses (<a href="./references#CD011265-bbs2-0023" title="HigginsJPT , DeeksJJ , Altman DGeditor(s) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>We tried to contact all trial authors for clarification of missing data. However, we did not receive any responses. </p> </section> <section id="CD011265-sec-0069"> <h4 class="title">Assessment of heterogeneity</h4> <p>We measured inconsistency among the pooled estimates using the I² test (I² = [(Q ‐ df)/Q] x 100%), where Q is the Chi² statistic and df is degrees of freedom. The I² statistic is a measure of the percentage of variability in effect estimates resulting from heterogeneity rather than sampling error (<a href="./references#CD011265-bbs2-0016" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>; <a href="./references#CD011265-bbs2-0022" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analysis. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). </p> <p>As strict thresholds for interpretation of I² are not recommended, we followed the rough guide to interpretation in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011265-bbs2-0016" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> <p> <ul id="CD011265-list-0005"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> <p>When I² lay in an area of overlap between two categories (e.g. between 50% and 60%), we considered differences in participants and interventions among the trials contributing data to the analysis (<a href="./references#CD011265-bbs2-0016" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD011265-sec-0070"> <h4 class="title">Assessment of reporting biases</h4> <p>If future versions of the review include a sufficient number of studies (more than 10), we will assess publication bias by drawing a funnel plot (trial effect versus trial size) (<a href="./references#CD011265-bbs2-0023" title="HigginsJPT , DeeksJJ , Altman DGeditor(s) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We could not draw a funnel plot because the number of included studies was insufficient. </p> </section> <section id="CD011265-sec-0071"> <h4 class="title">Data synthesis</h4> <section id="CD011265-sec-0072"> <h5 class="title">Qualitative information</h5> <p>We reported qualitative information relative to methods, risk of bias, description of participants, and outcome measures in the '<a href="./references#CD011265-sec-0143" title="">Characteristics of included studies</a>' tables. We did not include qualitative (non‐randomised) studies in the review. </p> </section> <section id="CD011265-sec-0073"> <h5 class="title">Quantitative information</h5> <p>We would have used a fixed‐effect model in the meta‐analysis of studies that were very homogeneous, that is, in which the characteristics of the design, population, interventions, comparators, and outcomes were similar. However, we used a random‐effects model, as the included trials were heterogeneous (<a href="./references#CD011265-bbs2-0016" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> <p>The two comparisons were not suitable for combination and we reported their results separately. </p> </section> <section id="CD011265-sec-0074"> <h5 class="title">'Summary of findings' table</h5> <p>We created `Summary of findings tables' for all comparisons and included the following prespecified outcomes (reported at a minimum of six months after treatment). </p> <p> <ul id="CD011265-list-0006"> <li> <p><b>Pain</b>: measured using a validated scoring system such as a VAS or numerical rating scale, reported preferably as the proportion of participants with at least 30% (moderate) pain relief over baseline. </p> </li> <li> <p><b>Functional impairment and disability</b>: assessed by change in the NIS or NDS in the lower extremities. </p> </li> <li> <p><b>Impairment of sensation</b>: assessed by the change in a quantitative sensory test ‐ vibration perception threshold. </p> </li> <li> <p><b>Impairment of sensation</b>: assessed by the change in a quantitative sensory test ‐ thermal threshold. </p> </li> <li> <p>A<b>dverse events</b>: any adverse event, adverse events requiring withdrawal, and serious adverse events. </p> </li> <li> <p><b>Symptom quality and severity</b>: assessed by the change in score on a validated screening questionnaire (NSS or MNSI). </p> </li> </ul> </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence (studies that contributed data to the prespecified outcomes). We used the methods and recommendations described in Chapters 11 and 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> using GRADEpro software (<a href="./references#CD011265-bbs2-0021" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed prior to 7 February 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a>; <a href="./references#CD011265-bbs2-0033" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , AklE , et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2011a</a>; <a href="./references#CD011265-bbs2-0034" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , AklE , Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2011b</a>). We downgraded our certainty in the evidence once if any single GRADE consideration applied to a serious degree and twice if very serious. We justified all decisions to downgrade or upgrade the certainty of the evidence in footnotes, and we made comments to aid readers' understanding of the review where necessary. </p> </section> </section> <section id="CD011265-sec-0075"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we found substantial heterogeneity, we investigated the possible causes by exploring the impact of risk of bias and participant characteristics. If we found sources of heterogeneity, and if there were sufficient data, we conducted meta‐analysis by subgroups (for example, by dosage, participant age, and type of diabetes): </p> <p> <ul id="CD011265-list-0007"> <li> <p>dosage: ≤ 1500 mg ALC daily for oral doses and ≤ 1000 mg daily for intravenous or intramuscular doses versus &gt; 1500 mg oral ALC daily or &gt; 1000 mg for intravenous or intramuscular doses (cut‐off based on half of the maximum dosage of ALC (3000 mg/day orally and 2000 mg/day intravenously) (<a href="./references#CD011265-bbs2-0007" title="Acetyl‐L‐carnitine. Monograph. Alternative Medicine Review2010;15(1):76‐83. [PUBMED: 20359271] ">Anon 2010</a>); </p> </li> <li> <p>age: since the presence of DPN depends directly on elevated glycaemic levels (<a href="./references#CD011265-bbs2-0036" title="TesfayeS , BoultonAJ , DyckPJ , FreemanR , HorowitzM , KemplerP , et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care2010;33(10):2285‐93. ">Tesfaye 2010</a>), there may be a stronger relationship between the prevalence of DPN and older age; </p> </li> <li> <p>type of diabetes: type 1 or type 2.</p> </li> </ul> </p> <p>According to sections 9.6.6 and 9.6.3.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, and because only two subgroups were available, we considered the results of subgroups by interpreting the tests for subgroup differences (<a href="./references#CD011265-bbs2-0016" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD011265-sec-0076"> <h4 class="title">Sensitivity analysis</h4> <p>In future versions of this review, if there are an adequate number of studies, we will perform sensitivity analyses to explore the robustness of the results. We will repeat the analysis excluding studies: </p> <p> <ul id="CD011265-list-0008"> <li> <p>that are unpublished;</p> </li> <li> <p>at high risk of bias;</p> </li> <li> <p>that assess outcomes after less than six months' treatment;</p> </li> <li> <p>that include participants with 'probable' DPN according to the Toronto Consensus (<a href="./references#CD011265-bbs2-0036" title="TesfayeS , BoultonAJ , DyckPJ , FreemanR , HorowitzM , KemplerP , et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care2010;33(10):2285‐93. ">Tesfaye 2010</a>)). </p> </li> </ul> </p> <section id="CD011265-sec-0077"> <h5 class="title">Economics issues</h5> <p>We did not find sufficient economic data in the included studies, but in future versions of this review, if cost data are available, we will report them. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011265-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011265-sec-0078"></div> <section id="CD011265-sec-0079"> <h3 class="title">Description of studies</h3> <section id="CD011265-sec-0080"> <h4 class="title">Results of the search</h4> <p>Our searches identified 79 records from the following databases: Cochrane Neuromuscular Specialised Register 13, Cochrane Central Register of Controlled Trials (CENTRAL) 12, MEDLINE 26, Embase 28, and Latin American and Caribbean Health Science Information database (LILACS) 0. From the 79 initial references, removal of duplicates resulted in 45 records. We assessed 40 records as not relevant for this review. We assessed the full text of the six other studies for eligibility. We excluded two studies for defined reasons (see <a href="./references#CD011265-sec-0144" title="">Characteristics of excluded studies</a>), and included four studies for analysis. See <a href="#CD011265-fig-0001">Figure 1</a> for a PRISMA chart illustrating the study selection process. </p> </section> <section id="CD011265-sec-0081"> <h4 class="title">Included studies</h4> <p>See the <a href="./references#CD011265-sec-0143" title="">Characteristics of included studies</a> section. </p> <section id="CD011265-sec-0082"> <h5 class="title">Study characteristics</h5> <p>We included four studies, with a total of 907 participants (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>; <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>; <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>; <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>). These studies provided data for two different comparisons: </p> <p> <ul id="CD011265-list-0009"> <li> <p>acetyl‐L‐carnitine (ALC) versus placebo (675 participants; <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>, <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>; <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>) </p> </li> <li> <p>ALC versus methylcobalamin (232 participants; <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>) </p> </li> </ul> </p> <p>Only one study provided information about the period over which it was conducted (between August 2008 and March 2011) (<a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>). </p> <p>Three studies were multicenter RCTs (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>; <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>; <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>). <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> reported data from two different clinical trials in the same paper. <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> was a multicenter non‐inferiority randomised trial that compared ALC with methylcobalamin without a placebo comparison. </p> </section> <section id="CD011265-sec-0083"> <h5 class="title">Setting</h5> <p>A single paper reported the results from two multicentre studies with identical methods: one performed in the USA and Canada (<a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>), and the other in the USA, Canada, and Europe (<a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>). The two other trials were each performed in a single country: <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a> enrolled participants from 20 centres in Italy, <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> enrolled participants from eight centres in China. </p> </section> <section id="CD011265-sec-0084"> <h5 class="title">Participants</h5> <p>Participants included men and women, with an age range from 18 to 70 years old or more. Two studies included a preponderance of older adults (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>; <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>). In <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>, 50.2% were women, whereas <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> had a slight preponderance of men (52.5%). <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> did not provided detailed information about age and gender. Participants with either type 1 or type 2 diabetes who met clinical and/or neurophysiological criteria for DPN were eligible for all studies. </p> <p>Since <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> presented incomplete data regarding the number of participants; we could not determine the number of participants analysed in each group for the majority of outcomes. We contacted the trial authors for clarification, but did not receive an answer. </p> </section> <section id="CD011265-sec-0085"> <h5 class="title">Sample size</h5> <p><a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a> included 333 participants, <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> included 232 participants, and <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> together included 342 participants, but the paper did not specify the numbers in each study. <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> did not evaluate all outcomes in all 1335 participants who were randomised. The numbers of participants from <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> included in <a href="./references#CD011265-fig-0004" title="">Analysis 1.1</a> were considerably smaller than the numbers of participants randomised. Pain was measured only in participants who reported pain as their most bothersome symptom at baseline (342/1335; 25.6%). The study reported sural nerve biopsy findings in 87% of the participants who underwent a baseline biopsy (245 evaluable pairs of biopsies) and limited the analysis to participants from US and Canadian centres, excluding European centres. Only <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> provided information about power and sample size calculation. </p> </section> <section id="CD011265-sec-0086"> <h5 class="title">Interventions</h5> <p>The four included studies administered ALC orally at different dosages and for different periods: </p> <p> <ul id="CD011265-list-0010"> <li> <p>1500 mg/day (for 24 weeks in <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> and for one year in <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>); </p> </li> <li> <p>2000 mg/day (for 355 days in <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>); </p> </li> <li> <p>3000 mg/day (for one year in <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>). </p> </li> </ul> </p> <p><a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a> started the intervention with intramuscular ALC at a dosage of 1000 mg/day for 10 days, and continued ALC orally as described above. </p> </section> <section id="CD011265-sec-0087"> <h5 class="title">Outcomes</h5> <p>Three of four included studies reported the review primary outcome (pain) as an end point (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>; <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>; <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>). Only <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> used a validated neuropathy functional impairment or disability scale (the Neuropathy Disability Score) or a validated symptom quality and severity scale (the Neuropathy Symptom Score). Only <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> reported quantitative sensory testing and sural nerve biopsy parameters. None of the included studies reported quality of life. All trials evaluated neurophysiological measures (nerve conduction velocities (NCVs) and sensory and motor nerve amplitudes), and adverse events. </p> </section> </section> <section id="CD011265-sec-0088"> <h4 class="title">Excluded studies</h4> <p>We excluded two studies. In the first study, the purpose of the intervention was to prevent foot ulceration (<a href="./references#CD011265-bbs2-0005" title="AbbottCA , VileikyteL , WilliamsonS , CarringtonAL , BoultonAJM , ALCAR Foot Ulcer Study Group. Effect of treatment with acetyl‐l‐carnitine on diabetic foot ulceration in patients with peripheral neuropathy: a 1 year prospective multi‐centre study. Diabetologia1997;40(Suppl 1):A556; Abstract no: 2184. [DOI: 10.1007/BF03162081] ">Abbott 1997</a>). The second was a pilot study with a very small number of participants (20) and a duration of only 15 days (<a href="./references#CD011265-bbs2-0006" title="QuatraroA , RocaP , DonzellaC , AcamporaR , MarfellaR , GiuglianoD . AcetyI‐L‐carnitine for symptomatic diabetic neuropathy. Diabetologia1995;38:123. ">Quatraro 1995</a>). See <a href="./references#CD011265-sec-0144" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD011265-sec-0089"> <h3 class="title">Risk of bias in included studies</h3> <p>We presented the risk of bias of each included study in the '<a href="./references#CD011265-sec-0143" title="">Characteristics of included studies</a>' tables. <a href="#CD011265-fig-0002">Figure 2</a> summarises the review authors' 'Risk of bias' judgments for all included studies. We judged two studies at low risk of bias (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>; <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>) and the other two studies at high risk of bias (<a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>; <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>). </p> <div class="figure" id="CD011265-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (‐) = high risk of bias." data-id="CD011265-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (‐) = high risk of bias. </p> </div> </div> </div> <section id="CD011265-sec-0090"> <h4 class="title">Allocation</h4> <p>Two studies reported methods of randomisation and allocation concealment and we rated them at low risk of bias (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>; <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>). The other two studies did not report these procedures and we rated them at unclear risk of bias (<a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>; <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>). </p> </section> <section id="CD011265-sec-0091"> <h4 class="title">Blinding</h4> <p>Participants and investigators were blinded to the interventions in <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>, which we rated at low risk of bias. We rated <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> at unclear risk of performance and detection bias, as there was insufficient information about blinding. <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a> did not provide information on assessor blinding, for which we judged it at unclear risk of detection bias. </p> </section> <section id="CD011265-sec-0092"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a> reported a loss to follow‐up of 11.7% (39/333), with no clear mention of ITT analysis. Although it is probable that <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a> performed an ITT analysis, because they reported something as 'overall clinical evaluation, which included all patients randomised', we rated this study as unclear risk of bias. In <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>, there was a 12% loss to follow‐up (28/232), with an ITT analysis; thus, we rated this study at low risk of bias. In <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>, of 1335 randomised participants, only those who received at least one dose of study medication and had one valid post‐randomisation electromyographic assessment were included in the analysis. Sural nerve biopsies were performed only in participants from North American Centres. Of these participants, 87% (245/282) provided an evaluable pair of biopsies. Since these participants differed from the European participants in important ways (e.g. they had a shorter duration of diabetes, were heavier, a smaller proportion had type I diabetes, and a greater proportion were people of colour), this represented a high risk of bias. </p> </section> <section id="CD011265-sec-0093"> <h4 class="title">Selective reporting</h4> <p>Two studies reported all prespecified outcomes and we rated them at low risk of bias (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>; <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>). Most outcomes from the two trials reported in the single paper were not reported separately. Reporting was incomplete, for example, because in the analyses of outcomes other than pain and adverse events, the trial authors presented incomplete data. Therefore, we rated these studies at high risk of bias (<a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>). </p> </section> <section id="CD011265-sec-0094"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a> and <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> appeared to be free from other sources of bias. Pain was investigated in only a proportion of the participants in <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> (those who reported pain as their most bothersome symptom). As it is unclear whether blinding and allocation concealment were adequate, knowledge of intervention groups could, in principle, have influenced inclusion of participants in the pain analysis. We rated these studies at unclear risk of bias in relation to the effects of ALC on pain. </p> </section> </section> <section id="CD011265-sec-0095"> <h3 class="title" id="CD011265-sec-0095">Effects of interventions</h3> <p>See: <a href="./full#CD011265-tbl-0001"><b>Summary of findings for the main comparison</b> Acetyl‐L‐carnitine compared to placebo for the treatment of diabetic polyneuropathy</a>; <a href="./full#CD011265-tbl-0002"><b>Summary of findings 2</b> Acetyl‐L‐carnitine compared to methylcobalamin for the treatment of diabetic polyneuropathy</a> </p> <section id="CD011265-sec-0096"> <h4 class="title">Acetyl‐L‐carnitine versus placebo</h4> <p>Three studies compared ALC with placebo and reported the results as mean ± standard deviation (SD) (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>; <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>; <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>). See <a href="./full#CD011265-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD011265-sec-0097"> <h5 class="title">Primary outcome: pain</h5> <p>We had planned to evaluate this outcome as the proportion of participants with a moderate (30%) or substantial (50%) improvement in pain, but this was not possible with the available data. </p> <p>Three studies comparing ALC and placebo reported pain as an outcome and measured it using a visual analogue scale (0 to 100 mm, on which higher scores indicate worse pain) (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>; <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>; <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>). At 6‐ to 12‐months' follow‐up, the mean change in pain from baseline favoured ALC over placebo (MD ‐9.16, 95% CI ‐16.76 to ‐1.57; three studies; 540 participants; I² = 56%; random‐effects; <a href="./references#CD011265-fig-0004" title="">Analysis 1.1</a>; <a href="#CD011265-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD011265-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Acetyl‐L‐carnitine versus placebo, outcome: 1.1 Pain at 6 to 12 months' follow‐up." data-id="CD011265-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Acetyl‐L‐carnitine versus placebo, outcome: 1.1 Pain at 6 to 12 months' follow‐up. </p> </div> </div> </div> <p>We judged the certainty of evidence to be very low, because of study limitations, indirectness (as ALC does not have a direct function on pain relief and pain was reported as a mean change), inconsistency of effect (possibly owing to differences in ALC dose), and imprecision. </p> <section id="CD011265-sec-0098"> <h6 class="title">Subgroup analysis</h6> <p>In the subgroup analysis, we observed that the combined pain results of the subgroup that received over 1500 mg/day ALC favoured ALC over placebo at 6 to 12 months' follow‐up, without heterogeneity (MD ‐14.93, 95% CI: ‐19.16 to ‐10.70; three studies; 381 participants; I² = 0%; <a href="./references#CD011265-fig-0004" title="">Analysis 1.1</a>; <a href="#CD011265-fig-0003">Figure 3</a>). The subgroup of participants who received 1500 mg/day or less did not show a clear difference between ALC and placebo in pain at 12 months' follow‐up (MD ‐0.05, 95% CI: ‐10.00 to 9.89; two studies; 159 participants; I² = 0%). Statistical tests for subgroup differences revealed a significant difference between the over 1500 mg/day subgroup and the below 1500 mg/day subgroup, which was also reflected in the high heterogeneity (Chi² = 7.28, df = 1 (P = 0.007), I² = 86.3%). These analyses included very few trials and should be interpreted very cautiously. </p> <p>We were not able to carry out other subgroup and sensitivity analyses because the reports did not provide enough data. </p> </section> </section> <section id="CD011265-sec-0099"> <h5 class="title">Secondary outcomes</h5> <section id="CD011265-sec-0100"> <h6 class="title">Functional impairment and disability</h6> <p>The included studies did not measure this outcome.</p> </section> <section id="CD011265-sec-0101"> <h6 class="title">Impairment of sensation</h6> <p><a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> reported this outcome, but incompletely. The study authors reported partial results from the two multicenter studies in the same paper. According to the study authors, at 12 months' follow‐up, the group that received ALC 3000 mg/day had better vibration perception in the fingers compared to the placebo group (no total numerical data provided; O’Brien’s rank scores). We graded this evidence as very low certainty due to very serious study limitations (the included studies were at high risk of reporting bias as no total numerical data were available). The trials were not reported separately and we do not know if the results were consistent. Therefore, we must be very uncertain about the estimate. </p> </section> <section id="CD011265-sec-0102"> <h6 class="title">Quality of life</h6> <p>The included studies did not measure this outcome.</p> </section> <section id="CD011265-sec-0103"> <h6 class="title">Neurophysiological measures</h6> <p>In <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>, the trial authors reported that the ALC group had more improvement in sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) at 12 month' follow‐up than the placebo group. Note that the quoted P values are those of the trial authors and do no take multiple testing into account. See <a href="#CD011265-tbl-0003">Table 1</a>. </p> <div class="table" id="CD011265-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Nerve conduction velocity measurements at 12 months' follow‐up (De Grandis 2002)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Nerve conduction velocity measurements at 12 months' follow‐up (</b><a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] "><b>De Grandis 2002</b> </a><b>)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>ALC (&gt; 1500 mg/day)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change (m/s)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change (m/s)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar SNCV</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sural SNCV</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median SNCV</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.05</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar MNCV</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peroneal MNCV</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median MNCV</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ALC: acetyl‐L‐carnitine; MNCV: motor nerve conduction velocity; SD: standard deviation; SNCV: sensory nerve conduction velocity </p> </div> </div> <p>In <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>, ALC also significantly improved sural and median sensory nerve amplitudes and median, ulnar, and peroneal motor nerve amplitudes, when compared with placebo. See <a href="#CD011265-tbl-0004">Table 2</a>. </p> <div class="table" id="CD011265-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Nerve amplitude measurements at 12 months' follow‐up (De Grandis 2002)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Nerve amplitude measurements at 12 months' follow‐up (</b><a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] "><b>De Grandis 2002</b> </a><b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>ALC (&gt; 1500 mg/day)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar SN (µV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant (P = not available)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sural SN (µV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median SN (µV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peroneal MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.05</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ALC: acetyl‐L‐carnitine; MN: motor nerve; SD: standard deviation; SN: sensory nerve</p> </div> </div> <p><a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> reported that in participants taking 1500 mg/day or 3000 mg/day of ALC, none of the NCV or amplitude measures showed any significant changes compared to the placebo group; however, the trial authors did not provide numerical data. </p> <p>The neurophysiological results should be viewed with caution, since there is no information about the total number of participants evaluated, and no numerical data in <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>. Further, there was a 41.7% loss to follow‐up for this outcome (results are reported for only 194 of 333 participants) in <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>. It is uncertain whether changes of the reported magnitude have any clinical relevance. </p> </section> <section id="CD011265-sec-0104"> <h6 class="title">Adverse events</h6> <p>In <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>, six participants from the intervention group (6/147, 4.1%) and two from the placebo group (2/147, 1.4%) discontinued treatment due to adverse events. The reasons included headache, facial paraesthesia, and gastrointestinal disorders. There were no clear differences between the tolerability of ALC and placebo either on participants' or investigators' evaluations. </p> <p><a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> reported that the most common adverse events were pain, paraesthesia, and hyperaesthesias, but there were no dropouts due to adverse events. Fewer participants taking 3000 mg/day of ALC than participants taking placebo reported pain, paraesthesia, and hyperaesthesia. The trial authors reported that there were nine deaths, which were not related to drug treatment, and that the other dropouts were due to withdrawal of consent and protocol violation. The report did not provide any additional numerical data about adverse events. </p> <p>We assessed the certainty of evidence for the adverse event outcome as low, downgrading twice for study limitations (unclear risk of bias in multiple domains and a high risk of reporting bias in the absence of numerical data). We could not assess precision in the absence of numerical data. The two trials were not reported separately and we do not know if the results were consistent. </p> </section> <section id="CD011265-sec-0105"> <h6 class="title">Symptom quality and severity</h6> <p><a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> assessed symptoms, but did not use a validated scale. <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a> provided no data for this outcome. </p> </section> <section id="CD011265-sec-0106"> <h6 class="title">Sural nerve biopsy parameters</h6> <p>In <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>, morphometric evaluations of sural nerve biopsies revealed a significant improvement in all biopsy parameters in the group who received 1500 mg/day ALC, compared to placebo (144.1 ± 28.9 versus 132.6 ± 37.8; P = 0.027, O’Brien rank score), with a significant increase in fibre numbers (‐14 ± 197 versus ‐98 ± 352; P = 0.049), and a significantly greater number of regenerating clusters (‐3.3 ± 8.0 versus ‐27.9 ± 9.1; P = 0.033). However, for participants treated with ALC 3000 mg/day, there were no clear differences compared with placebo (the reports did not provide any numerical data). This finding was despite the decreased pain with higher doses. These biopsy‐related results were at a high risk of bias, since the sample comprised only 245 pairs of biopsies from 1335 randomised participants and European participants, who did not contribute samples, had different baseline characteristics than the North American participants. </p> </section> </section> </section> <section id="CD011265-sec-0107"> <h4 class="title">Acetyl‐L‐carnitine versus methylcobalamin</h4> <p>One study compared ALC (≤ 1500 mg/day) with methylcobalamin (0.5 mg three times per day) (<a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>). The trial authors tested an equivalence hypothesis of the two interventions for the treatment of diabetic neuropathy, and provided all numerical data as a mean ± SD. See <a href="./full#CD011265-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD011265-sec-0108"> <h5 class="title">Primary outcomes: pain</h5> <p>The included study did not measure this outcome.</p> </section> <section id="CD011265-sec-0109"> <h5 class="title">Secondary outcomes</h5> <section id="CD011265-sec-0110"> <h6 class="title">Functional impairment and disability</h6> <p>In <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>, participants from both groups had significant reductions in the NDS (range from zero to 10), compared to their respective baseline measurements (ALC, from 6.58 ± 2.19 to 5.55 ± 2.50, 117 participants; methylcobalamin, from 6.43 ± 2.04 to 5.08 ± 2.41, 115 participants), with no clear difference between the ALC and methylcobalamin groups at 24 weeks' follow‐up (ALC 1.66 ± 1.90 versus methylcobalamin 1.35 ± 1.65). This represents a MD of 0.31, 95% CI ‐0.15 to 0.77 (see <a href="./references#CD011265-fig-0005" title="">Analysis 2.1</a>). </p> <p>We downgraded the certainty of evidence twice: once for imprecision, as the evidence is from a single study involving 232 participants, and once for indirectness, as methylcobalamin is not an established treatment for DPN. The effects of methylcobalamin are uncertain, which makes it difficult to determine the effects of ALC. </p> </section> <section id="CD011265-sec-0111"> <h6 class="title">Measures of impairment of sensation</h6> <p>The included study did not measure this outcome.</p> </section> <section id="CD011265-sec-0112"> <h6 class="title">Quality of life</h6> <p>The included study did not measure this outcome.</p> </section> <section id="CD011265-sec-0113"> <h6 class="title">Neurophysiological measures</h6> <p><a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> assessed the SNCV and MNCV in the median and ulnar nerves, the sural SNCV, and the tibial and peroneal MNCVs. The trial reported that only the ulnar MNCV showed a statistically significant improvement with ALC in comparison to methylcobalamin after 24 weeks. The results in <a href="#CD011265-tbl-0005">Table 3</a> show the changes from baseline to week 24 for the two groups. </p> <div class="table" id="CD011265-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Nerve conduction velocity measurements at 12 months' follow‐up (Li 2016)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Nerve conduction velocity measurements at 12 months' follow‐up (</b><a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] "><b>Li 2016</b> </a><b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>ALC (≤ 1500 mg/day)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change (m/s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change (m/s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median SNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar SNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sural SNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median MNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar MNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tibial MNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peroneal MNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ALC: acetyl‐L‐carnitine; MNCV: motor nerve conduction velocity; SD: standard deviation; SNCV: sensory nerve conduction velocity </p> </div> </div> <p><a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> assessed action potential amplitudes in the same nerves. Only the ulnar sensory nerve amplitude showed a statistically significant improvement with ALC compared to methylcobalamin (88 participants). It is important to note that <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> considered a level of statistical significance of P &lt; 0.025. The results in <a href="#CD011265-tbl-0006">Table 4</a> are presented as mean change ± SD or mean (95% CI), and describe the change from baseline to week 24 for the two groups. </p> <div class="table" id="CD011265-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Nerve amplitude measurements at 12 months' follow‐up (Li 2016)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Nerve action potential amplitude measurements at 12 months' follow‐up (</b><a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] "><b>Li 2016</b> </a><b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>ALC (≤ 1500 mg/day)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI or SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI or SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median SN (µV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.07 to 3.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 3.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar SN (µV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.30 to 1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 11.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sural SN (µV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.10 to 1.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.95 to 1.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 6.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 2.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tibial MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.15 to 2.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.41 to 3.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peroneal MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.03 to 1.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 0.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ALC: acetyl‐L‐carnitine; CI: confidence interval; MN: motor nerve; SD: standard deviation; SN: sensory nerve </p> </div> </div> </section> <section id="CD011265-sec-0114"> <h6 class="title">Adverse events</h6> <p>In <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>, the proportion of participants reporting adverse events was similar in the ALC group (34/117, 29.1%) and the methylcobalamin group (33/115, 28.7%) (RR 1.01, 95% CI 0.68 to 1.52; 232 participants; <a href="./references#CD011265-fig-0006" title="">Analysis 2.2</a>). Four participants from the ALC group, and five from the methylcobalamin group had serious adverse events (RR 0.79, 95% CI 0.22 to 2.85; 232 participants; <a href="./references#CD011265-fig-0007" title="">Analysis 2.3</a>). Four participants from the ALC group and five from the methylcobalamin group discontinued treatment due to adverse events (RR 0.79, 95% CI 0.22 to 2.85; 232 participants; <a href="./references#CD011265-fig-0008" title="">Analysis 2.4</a>). The most common adverse events in both groups were gastrointestinal symptoms, such as abdominal distension, hiccups, and nausea. </p> <p>We judged the certainty of evidence to be low, downgrading once for imprecision, as the evidence was from a single study of 232 participants, and once for indirectness, as the comparator made it difficult to distinguish the adverse effects of ALC. </p> </section> <section id="CD011265-sec-0115"> <h6 class="title">Symptom quality and severity</h6> <p><a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> measured symptoms using the Neuropathy Symptom Scale (NSS; a scale from zero to 9, on which a higher score indicates worse symptoms). </p> <p>In <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>, participants in both groups had significant reductions in NSS from baseline to 24 weeks' follow‐up (ALC, from 6.52 ± 1.52 to 4.17 ± 2.45, 117 participants, P &lt; 0.0001; methylcobalamin, from 6.37 ± 1.71 to 4.25 ± 2.60, 115 participants, P &lt; 0.0001), with little difference between the ALC and methylcobalamin groups (2.35 ± 2.23 versus 2.11 ± 2.48, respectively; P = 0.38), for a MD of 0.24, 95% CI ‐0.37 to 0.85; <a href="./references#CD011265-fig-0009" title="">Analysis 2.5</a>). </p> <p>We downgraded the certainty of evidence twice: once for imprecision, as the evidence is from a single study involving 232 participants, and once for indirectness, as methylcobalamin is not an established treatment for DPN and, therefore, it is difficult to determine the effects of ALC from this study. </p> </section> <section id="CD011265-sec-0116"> <h6 class="title">Sural nerve biopsy parameters</h6> <p>The included study did not measure this outcome.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011265-sec-0117" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011265-sec-0117"></div> <section id="CD011265-sec-0118"> <h3 class="title" id="CD011265-sec-0118">Summary of main results</h3> <p>Three publications, describing four studies with a total of 907 randomised participants, were eligible for inclusion in this review. </p> <p>The two comparisons in the included studies were: 1) acetyl‐L‐carnitine (ALC) versus placebo (three studies, 675 participants) and 2) ALC versus methylcobalamin (one study, 232 participants). </p> <p>For the primary outcome, it was uncertain whether ALC (all doses) reduced pain compared to placebo, measured on a visual analogue scale (VAS). Doses higher than 1500 mg/day seemed to reduce pain more than placebo (three studies, 675 participants), while the subgroup of participants treated with 1500 mg/day showed little or no reduction in mean pain score compared to placebo (two studies, 159 participants). However, there were few studies and this subgroup analysis may not be reliable. The evidence was very uncertain for changes in measures of impairment, and symptom quality and severity. </p> <p>We identified no clear differences in adverse events or dropout rates between the ALC and placebo groups; however, the certainty of evidence was low, as data were limited and dropout rates were substantial, where reported. Two studies reported small numerical increases in nerve conduction velocity (NCV) in the ALC group versus placebo after 48 weeks of treatment (versus placebo) or versus methylcobalamin after 24 weeks of treatment. It is worth remembering that NCV is one of the main tests used to evaluate drug efficacy in DPN. However, it may not translate into any clinically useful effect, as it is an indirect measure of neuropathy improvement and can be influenced by multiple factors. </p> <p><a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> compared ALC with methylcobalamin. This trial did not assess pain. Data indicated little or no difference between the groups on measures of functional impairment and disability or the results of sural nerve biopsy. The adverse event data were also similar between the intervention groups. Although only 4/117 participants receiving ALC and 5/115 participants receiving methylcobalamin discontinued treatment because of adverse events, a considerable number of participants in both groups (29.1% in the ALC group and 28.7% in the methylcobalamin group) reported adverse events. </p> </section> <section id="CD011265-sec-0119"> <h3 class="title" id="CD011265-sec-0119">Overall completeness and applicability of evidence</h3> <p>This review primarily assessed whether ALC reduced pain in people with DPN. It also evaluated other parameters of neural function (functional impairment, measures of impairment of sensation, neurophysiological measures, and sural nerve biopsy parameters), quality of life, quality and severity of symptoms, and safety (adverse events). </p> <p>Three studies (540 participants) examined ALC versus placebo for the treatment of DPN, within apparently similar study populations. All three analysed and reported the primary outcome and some secondary outcomes prespecified in the protocol of this review (<a href="./references#CD011265-bbs2-0045" title="RolimLC , daSilvaEMK , KomatsuWR , AbreuM , DibSA . Acetyl‐L‐carnitine for the treatment of diabetic polyneuropathy. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD011265; CD011265] ">Rolim 2014</a>). They did not use validated scales to assess functional impairment and disability or symptom quality and severity, and did not measure quality of life. </p> <p>Heterogeneity was high in the ALC versus placebo comparison, mainly owing to the use of a low dose of the drug (1500 mg/day) in subgroups of participants in two studies (<a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>; <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>). Moreover, Sima and colleagues did not evaluate all outcomes in all enrolled participants, and presented incomplete data on participant numbers in each outcome evaluation. The number of included participants in <a href="./references#CD011265-fig-0004" title="">Analysis 1.1</a> was considerably smaller than the number randomised to each group. </p> <p>Each study of ALC versus placebo used a similar 10‐cm VAS for the primary outcome (pain). They also used similar inclusion criteria, which resulted in almost identical participant populations across studies in this comparison. </p> <p>We were able to perform a subgroup analysis for doses of 1500 mg/day or less and above 1500 mg/day. The analysis suggested different effects on pain by subgroup: at doses over 1500 mg/day, ALC reduced pain compared to placebo, whereas at doses of 1500 mg/day or less, ALC had no clear effect. However, the data are limited and the evidence is of very low certainty. The data suggested that dose might have accounted for the overall heterogeneity in <a href="./references#CD011265-fig-0004" title="">Analysis 1.1</a>. </p> <p>Data were available for at least four of our seven secondary outcomes. None of the included studies provided data sufficiently detailed to allow us to conduct a meta‐analysis for any of the secondary outcomes. The qualitative evaluation provided limited information, from one included study, that suggested improvement in neurophysiological measures in the ALC group compared to the placebo group. However, the results should be viewed with caution because of a high number of dropouts for these outcomes in <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>. <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> did not report the number of participants evaluated for quantitative sensory scores, neurophysiological measures, or sural nerve biopsies. The trial authors evaluated only 245 pairs of sural nerve biopsies from 1335 randomised participants, which reduced our confidence in these results. </p> <p>Three included placebo‐controlled studies provided very low‐certainty evidence on adverse events, showing no clear difference between the groups (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>; <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>; <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>). </p> <p>One study compared ALC with another intervention (methylcobalamin) (<a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>). This study did not provide information about pain (our primary outcome), quantitative sensory testing, quality of life, or sural nerve biopsies. There was limited information regarding four of our seven secondary outcomes, and only two of the neurophysiological measures favoured ALC over with methylcobalamin. <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> explained that the study lacked a placebo comparison because methylcobalamin had already been approved for DPN in China (where the study took place), and so the local ethical committee did not approve a placebo control. However, methylcobalamin is not approved for use in DPN by authorities in other jurisdictions such as the USA (<a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank">www.accessdata.fda.gov/scripts/cder/daf/index.cfm</a>) or Europe (<a href="http://www.ema.europa.eu/ema/" target="_blank">www.ema.europa.eu/ema/</a>), since there is a lack of evidence addressing the effects of methylcobalamin for the treatment of DPN. Therefore, it is difficult to interpret the finding from <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a> that there may be little or no difference between the effects of ALC and methylcobalamin, because it is possible that both interventions have similar effects. </p> <p>In summary, we lack data:</p> <p> <ul id="CD011265-list-0011"> <li> <p>of any certainty on the effects of ALC versus placebo at 6 to 12 months;</p> </li> <li> <p>on longer‐term follow‐up, i.e. follow‐up for more than one year;</p> </li> <li> <p>comparing the effect of ALC on the two main types of diabetes (type 1 and type 2);</p> </li> <li> <p>from different populations. There were data from America, Europe, and Asia; however, data from other continents is needed to increase the external validity of the results </p> </li> </ul> </p> </section> <section id="CD011265-sec-0120"> <h3 class="title" id="CD011265-sec-0120">Quality of the evidence</h3> <p>We identified three publications, reporting on four studies with a total of 907 participants. Three trials studied ALC versus placebo; in one, the dose of ALC was 2000 mg/day, and in the other two it was 1500 mg/day or 3000 mg/day (675 participants). The risk of bias was high in both trials of different ALC doses and unclear in the ALC 2000 mg/day trial. The fourth trial studied ALC (at ≤ 1500 mg/day) versus methylcobalamin (232 participants) and was at low risk of bias. </p> <p>For pain after 12 months, we downgraded the certainty of the evidence three times to very low, because there were very serious study limitations, measurement of the outcome was indirect, and the result was imprecise, with a CI that encompassed both little or no effect and a clinically important effect. There was also a high level of heterogeneity in the overall pain analysis, although this may be explained by dosage. Although pain is routinely reported using scores on a rating scale (continuous data), we planned to report a responder analysis (the proportion of participants with substantial and moderate reductions in pain), which is the preferred measure in Cochrane reviews of treatments for neuropathic pain (<a href="./references#CD011265-bbs2-0027" title="CochranePain , Palliative &amp; Supportive Care Review Group. Authoring or assessing a Cochrane Protocol, Review, or Review Update for the PaPaS Review Group, 2011. Available from: papas.cochrane.org/sites/papas.cochrane.org/files/public/uploads/L%20‐%20PaPaSAuthor%26RefereeGuidance.pdf. ">PaPaS 2011</a>). </p> <p>Two placebo‐controlled studies reported that NCVs and amplitudes did not improve with ALC (≤ 1500 mg/day and &gt; 1500 mg/day), whereas vibration perception improved after 12 months but did not provide numerical data. Another included placebo‐controlled study reported a significant statistical improvement favouring the ALC group in terms of NCVs of all investigated nerves; however, only 194 of 333 participants (41.7%) completed the neurophysiological studies at the end of the trial and the figures for neurophysiological improvement are unreliable (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>). The placebo‐controlled studies did not assess functional impairment scores. <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> performed sensory testing, but the certainty of evidence was very low due to very serious study limitations. The trials were not reported separately and we do not know if the results were consistent. </p> <p>The fourth included study compared ALC ≤ 1500 mg/day with methylcobalamin, but did not report effects on pain or sensation. Both groups showed reductions in functional impairment and disability, and improvement in some neurophysiological parameters (NCVs and amplitudes) from baseline to 24 weeks, with no clear differences between the ALC and methylcobalamin groups. We judged the certainty of evidence to be very low for all reported outcomes, downgrading it once for indirectness and twice for imprecision. </p> <p>In one placebo‐controlled study, eight participants discontinued the treatment due to adverse events (six in the ALC group and two in the placebo group). The two other placebo‐controlled studies reported no dropouts due to adverse events, and more adverse events in the placebo group than the ALC &gt; 1500 mg/day group (without numerical data). The overall certainty of the evidence on adverse events for the comparison of ALC versus placebo was low. </p> <p>The study comparing ALC with methylcobalamin also reported dropouts due to adverse events, with no clear difference between the ALC ≤ 1500 mg/day group (4 participants) and the methylcobalamin group (5 participants). We assessed the certainty of the evidence on adverse events for the comparison of ALC versus methylcobalamin as low; we downgraded it once for imprecision and once for indirectness. </p> <p>All included studies involved the manufacturers of ALC. Two were clearly funded, and the other two had at least one co‐author who was a consultant for an ALC manufacturer. </p> </section> <section id="CD011265-sec-0121"> <h3 class="title" id="CD011265-sec-0121">Potential biases in the review process</h3> <p>We believe that we identified and included all relevant studies. We identified duplicate reports of studies in the selection process and searched multiple sources, with no language restriction. However, the possibility remains that we may have missed some trials, particularly in the grey literature. We adhered to the inclusion and exclusion criteria prespecified in the protocol in order to limit subjectivity (<a href="./references#CD011265-bbs2-0045" title="RolimLC , daSilvaEMK , KomatsuWR , AbreuM , DibSA . Acetyl‐L‐carnitine for the treatment of diabetic polyneuropathy. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD011265; CD011265] ">Rolim 2014</a>). We made efforts to obtain additional relevant data from study authors, but were unable to do so. If we can source supplementary data, we will consider them in future updates. We followed standard methodological procedures to reduce bias in the review process. </p> <p>It should be noted that reviews that include a small number of trials, such as ours, have limitations in relation to events that occur infrequently, such as adverse events. </p> </section> <section id="CD011265-sec-0122"> <h3 class="title" id="CD011265-sec-0122">Agreements and disagreements with other studies or reviews</h3> <p>We identified two published systematic reviews, including one meta‐analysis reporting on the effects of ALC for the treatment of DPN. </p> <p><a href="./references#CD011265-bbs2-0026" title="LiS , LiQ , LiY , LiL , TianH , SunX . Acetyl‐L‐carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta‐analysis of randomized controlled trials. PloS One2015;10(3):e0119479. [PUBMED: 25751285] ">Li 2015</a> reviewed the efficacy and safety of ALC for the treatment of people with peripheral neuropathic pain. In contrast with our review, <a href="./references#CD011265-bbs2-0026" title="LiS , LiQ , LiY , LiL , TianH , SunX . Acetyl‐L‐carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta‐analysis of randomized controlled trials. PloS One2015;10(3):e0119479. [PUBMED: 25751285] ">Li 2015</a> only evaluated pain and included three of the studies (384 participants) included in our review (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>; <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>; <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>). <a href="./references#CD011265-bbs2-0026" title="LiS , LiQ , LiY , LiL , TianH , SunX . Acetyl‐L‐carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta‐analysis of randomized controlled trials. PloS One2015;10(3):e0119479. [PUBMED: 25751285] ">Li 2015</a> only included studies published in English. Li and colleagues concluded that ALC had a moderate effect on reducing pain, as measured on a VAS, in people with peripheral neuropathic pain, and that there was acceptable safety associated with the treatment, despite the fact that the evidence was too limited to draw a definitive conclusion. Our conclusions are more circumspect. </p> <p><a href="./references#CD011265-bbs2-0037" title="VeroneseN , SergiG , StubbsB , Bourdel‐MarchassonI , TessierD , SieberC , et al. the EUGMS special interest group on diabetes. Effect of acetyl‐l‐carnitine in the treatment of diabetic peripheral neuropathy: a systematic review and meta‐analysis. European Geriatric Medicine2017;8(2):117‐22. [DOI: 10.1016/j.eurger.2017.01.002] ">Veronese 2017</a> investigated six studies, which included 711 participants with DPN (with <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> counted as a single study). In addition to the RCTs analysed in our review (<a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>; <a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] ">Li 2016</a>; <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>; <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>), the authors included three observational studies without a control group, which were conducted in Turkey. These studies involved 53 participants with type 1 and type 2 diabetes. Their median follow‐up period was short (8 weeks, range two to 40 weeks). The <a href="./references#CD011265-bbs2-0037" title="VeroneseN , SergiG , StubbsB , Bourdel‐MarchassonI , TessierD , SieberC , et al. the EUGMS special interest group on diabetes. Effect of acetyl‐l‐carnitine in the treatment of diabetic peripheral neuropathy: a systematic review and meta‐analysis. European Geriatric Medicine2017;8(2):117‐22. [DOI: 10.1016/j.eurger.2017.01.002] ">Veronese 2017</a> review was funded by an unrestricted grant from Sigma‐Tau. Although the authors of <a href="./references#CD011265-bbs2-0037" title="VeroneseN , SergiG , StubbsB , Bourdel‐MarchassonI , TessierD , SieberC , et al. the EUGMS special interest group on diabetes. Effect of acetyl‐l‐carnitine in the treatment of diabetic peripheral neuropathy: a systematic review and meta‐analysis. European Geriatric Medicine2017;8(2):117‐22. [DOI: 10.1016/j.eurger.2017.01.002] ">Veronese 2017</a> concluded that ALC seemed to be effective in reducing pain due to DPN and improving electromyographic parameters, the meta‐analysis combined pain data from all the trials in our review, including the comparison of ALC and methylcobalamin, and included very substantial heterogeneity (I² = 86%). The authors of <a href="./references#CD011265-bbs2-0037" title="VeroneseN , SergiG , StubbsB , Bourdel‐MarchassonI , TessierD , SieberC , et al. the EUGMS special interest group on diabetes. Effect of acetyl‐l‐carnitine in the treatment of diabetic peripheral neuropathy: a systematic review and meta‐analysis. European Geriatric Medicine2017;8(2):117‐22. [DOI: 10.1016/j.eurger.2017.01.002] ">Veronese 2017</a> found the trials at low risk of bias using the Jadad scale; which is not consistent with our assessments of high risk for <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a> and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a>, and unclear risk for <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>, using the Cochrane 'Risk of bias tool'. Furthermore, potential changes in nerve temperature (as described by <a href="./references#CD011265-bbs2-0044" title="ZochodneDW . Sensory neurodegeneration in diabetes: beyond glucotoxicity. International Review of Neurobiology2016;127:151‐80. [PUBMED: 27133149] ">Zochodne 2016</a>) could explain the improvement in NCV that was found in <a href="./references#CD011265-bbs2-0037" title="VeroneseN , SergiG , StubbsB , Bourdel‐MarchassonI , TessierD , SieberC , et al. the EUGMS special interest group on diabetes. Effect of acetyl‐l‐carnitine in the treatment of diabetic peripheral neuropathy: a systematic review and meta‐analysis. European Geriatric Medicine2017;8(2):117‐22. [DOI: 10.1016/j.eurger.2017.01.002] ">Veronese 2017</a>. The dosage of ALC was highly variable among the studies, and some participants received L‐carnitine and not acetyl‐L‐carnitine. The bioavailability of ALC is better than that of L‐carnitine because the acetyl group enables the ALC molecule to cross the blood‐brain barrier more easily. In addition, ALC can also provide more acetyl groups for the synthesis of acetylcholine, a crucial neurotransmitter in the nervous system. Taking into consideration these weaknesses, the conclusions of <a href="./references#CD011265-bbs2-0037" title="VeroneseN , SergiG , StubbsB , Bourdel‐MarchassonI , TessierD , SieberC , et al. the EUGMS special interest group on diabetes. Effect of acetyl‐l‐carnitine in the treatment of diabetic peripheral neuropathy: a systematic review and meta‐analysis. European Geriatric Medicine2017;8(2):117‐22. [DOI: 10.1016/j.eurger.2017.01.002] ">Veronese 2017</a> regarding ALC and L‐carnitine for DPN should be viewed with caution. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011265-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/urn:x-wiley:14651858:media:CD011265:CD011265-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_t/tCD011265-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow chart illustrating the study selection process for the review." data-id="CD011265-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow chart illustrating the study selection process for the review.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011265-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/urn:x-wiley:14651858:media:CD011265:CD011265-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_t/tCD011265-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (‐) = high risk of bias." data-id="CD011265-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (‐) = high risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011265-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/urn:x-wiley:14651858:media:CD011265:CD011265-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_t/tCD011265-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Acetyl‐L‐carnitine versus placebo, outcome: 1.1 Pain at 6 to 12 months' follow‐up." data-id="CD011265-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Acetyl‐L‐carnitine versus placebo, outcome: 1.1 Pain at 6 to 12 months' follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011265-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/urn:x-wiley:14651858:media:CD011265:CD011265-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_t/tCD011265-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Acetyl‐L‐carnitine versus placebo, Outcome 1 Pain at 6 to 12 months' follow‐up." data-id="CD011265-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Acetyl‐L‐carnitine versus placebo, Outcome 1 Pain at 6 to 12 months' follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/references#CD011265-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011265-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/urn:x-wiley:14651858:media:CD011265:CD011265-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_t/tCD011265-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Acetyl‐L‐carnitine versus methylcobalamin, Outcome 1 Functional impairment and disability (change in Neurological Disability Scale) at 24 weeks' follow‐up." data-id="CD011265-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Acetyl‐L‐carnitine versus methylcobalamin, Outcome 1 Functional impairment and disability (change in Neurological Disability Scale) at 24 weeks' follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/references#CD011265-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011265-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/urn:x-wiley:14651858:media:CD011265:CD011265-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_t/tCD011265-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Acetyl‐L‐carnitine versus methylcobalamin, Outcome 2 Adverse events." data-id="CD011265-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Acetyl‐L‐carnitine versus methylcobalamin, Outcome 2 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/references#CD011265-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011265-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/urn:x-wiley:14651858:media:CD011265:CD011265-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_t/tCD011265-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Acetyl‐L‐carnitine versus methylcobalamin, Outcome 3 Serious adverse events." data-id="CD011265-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Acetyl‐L‐carnitine versus methylcobalamin, Outcome 3 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/references#CD011265-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011265-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/urn:x-wiley:14651858:media:CD011265:CD011265-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_t/tCD011265-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Acetyl‐L‐carnitine versus methylcobalamin, Outcome 4 Adverse events leading to withdrawal." data-id="CD011265-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Acetyl‐L‐carnitine versus methylcobalamin, Outcome 4 Adverse events leading to withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/references#CD011265-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011265-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/urn:x-wiley:14651858:media:CD011265:CD011265-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_t/tCD011265-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Acetyl‐L‐carnitine versus methylcobalamin, Outcome 5 Symptom quality and severity (change in Neuropathy Symptom Score) at 24 weeks' follow‐up." data-id="CD011265-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Acetyl‐L‐carnitine versus methylcobalamin, Outcome 5 Symptom quality and severity (change in Neuropathy Symptom Score) at 24 weeks' follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/references#CD011265-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/media/CDSR/CD011265/image_n/nCD011265-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011265-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Acetyl‐L‐carnitine compared to placebo for the treatment of diabetic polyneuropathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Acetyl‐L‐carnitine compared to placebo for the treatment of diabetic peripheral neuropathy (DPN)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic peripheral neuropathy<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> acetyl‐L‐carnitine (ALC; 1500 mg/day to 3000 mg/day)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Acetyl‐L‐carnitine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> at 6 months or more; all doses </p> <p>Assessed by change from baseline, using a 0‐ to 100‐mm VAS, where higher scores indicate more pain) </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The control group baseline average VAS score was 49.2<sup>a</sup> </p> <p>The average improvement in the control groups was 10.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS pain score improved on average 9.16 points more (1.57 to 16.76 points more) than in the placebo group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>540<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b,c,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional impairment and disability</b> </p> <p>Assessed by NIS or NDS at 6 months or more</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Included studies did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Impairment of sensation</b> </p> <p>Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The group that received ALC 3000 mg/day had better vibration perception than the placebo group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> <p>2 RCTs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>d,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 2 RCTs that measured this outcome did not provide complete data. Not measured in a 3rd trial </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Impairment of sensation</b> </p> <p>Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Included studies did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptom quality and severity</b> </p> <p>Assessed by change in symptom score on a validated screening questionnaire (NSS or MNSI) at 6 months or more </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Although 2 other studies assessed symptoms, the scale used was not validated. A 3rd study did not assess symptom quality and severity. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b>: any adverse event, adverse events requiring withdrawal, and serious adverse events </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study found no clear difference in withdrawals in the intervention group (4.1%) compared with the placebo group (1.4%, P = 0.17). </p> <p>1 study reported no dropouts due to adverse events, and less pain (P = 0.026), paraesthesia (P = 0.023), and hyperaesthesias (P = 0.025) in the 3000 mg/day ALC group than the placebo group. </p> <p>1 study provided no numerical data.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>540<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ALC</b> : acetyl‐L‐carnitine; <b>CI</b> : confidence interval; <b>MNSI</b> : Michigan Neuropathy Screening Instrument; <b>NDS</b> : Neuropathy Disability Score; <b>NIS</b> : Neuropathy Impairment Score; <b>NSS</b> : Neuropathy Symptom Score; <b>RCT</b> : randomised controlled trial; <b>VAS</b>: visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Mean baseline scores from included studies (score estimated from a graph in <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a>).<br/> <sup>b</sup>Downgraded one level for indirectness: the outcome is indirectly related to the function of the intervention (ALC does not have a direct effect on pain relief), and we were unable to report the outcome as specified (i.e. the number with 30% pain relief).<br/> <sup>c</sup>Downgraded one level due to imprecision: the CI included the possibility of both a clinically important effect and little or no effect.<br/> <sup>d</sup>Downgraded one level for study limitations, due to an unclear risk of bias in three included studies in several domains. <a href="./references#CD011265-bbs2-0003" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005a</a>, and <a href="./references#CD011265-bbs2-0004" title="SimaAA , CalvaniM , MehraM , AmatoA , Acetyl‐L‐Carnitine Study Group. Acetyl‐L‐carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo‐controlled trials. Diabetes Care2005;28(1):89‐94. [PUBMED: 15616239] ">Sima 2005b</a> did not fully describe methods of randomisation, allocation concealment, or blinding. <a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] ">De Grandis 2002</a> was at an unclear risk of bias from attrition and blinding of outcome assessors. We also assessed the selection of participants for measurement of pain at unclear risk of bias.<br/> <sup>e</sup>Heterogeneity in the pain analysis was substantial (I² = 56% and differences between participants). This might be explained by differences in effect between ALC ≤ 1500 mg/day and &gt; 1500 mg/day subgroups.<br/> <sup>f</sup>Downgraded two levels: in the absence of numerical data, the outcome was at high risk of reporting bias, and precision could not be assessed. The two trials were not reported separately and we do not know if the results were consistent. We must therefore be very uncertain about the estimate.<br/> <sup>g</sup>Downgraded one level for reporting bias, as one trial did not provide data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Acetyl‐L‐carnitine compared to placebo for the treatment of diabetic polyneuropathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011265-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Acetyl‐L‐carnitine compared to methylcobalamin for the treatment of diabetic polyneuropathy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Acetyl‐L‐carnitine compared to methylcobalamin for the treatment of diabetic peripheral neuropathy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> the treatment of diabetic peripheral neuropathy<br/> <b>Setting:</b> outpatients, China<br/> <b>Intervention:</b> acetyl‐L‐carnitine (ALC, ≤ 1500 mg/day)<br/> <b>Comparison:</b> methylcobalamin (0.5 mg three times per day) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with methylcobalamin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with acetyl‐L‐carnitine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain</b> at 6 months or more </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional impairment and disability</b> </p> <p>Assessed by change in NDS score (range of possible scores from 0 (normal function) to 10 (maximal disability) </p> <p>Follow‐up: 24 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The methylcobalamin group baseline average NDS score was 6.43.</p> <p>The average improvement in the methylcobalamin group was 1.35 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The average NDS score improved 0.31 more in the ALC group than in the methylcobalamin group (0.15 less to 0.77 more). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Impairment of sensation</b>: quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Impairment of sensation</b>: quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptom quality and severity</b> </p> <p>Assessed by NSS score (range of possible scores 0 to 9; higher scores indicate more symptoms) </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The methylcobalamin group baseline average NSS score was 6.37</p> <p>The average change (decrease) in the methylcobalamin group was 2.11 points.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The average NSS score improved 0.24 more<br/> in the ALC group than in the methylcobalamin group (0.37 less to 0.85 more). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>287 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000<br/> (195 to 436) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.68 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>ALC</b> : Acetyl‐L‐carnitine; <b>CI</b> : confidence interval; <b>NDS</b> : Neuropathy Disability Score; <b>NIS</b> : Neuropathy Impairment Score; <b>NSS</b> : Neuropathy Symptom Score; <b>RCT</b> : randomised controlled trial; <b>VAS</b>: visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for indirectness, as the control intervention methylcobalamin is not an established treatment for DPN and its effects are uncertain.<br/> <sup>b</sup>Downgraded once for imprecision: the CI included the possibility of both a clinically important effect and little or no effect; small sample (232 participants).<br/> <sup>c</sup>Downgraded once for indirectness, as the comparator made it difficult to distinguish the adverse effects of ALC. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Acetyl‐L‐carnitine compared to methylcobalamin for the treatment of diabetic polyneuropathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011265-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Nerve conduction velocity measurements at 12 months' follow‐up (De Grandis 2002)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Nerve conduction velocity measurements at 12 months' follow‐up (</b><a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] "><b>De Grandis 2002</b> </a><b>)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>ALC (&gt; 1500 mg/day)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change (m/s)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change (m/s)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar SNCV</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sural SNCV</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median SNCV</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.05</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar MNCV</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peroneal MNCV</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median MNCV</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ALC: acetyl‐L‐carnitine; MNCV: motor nerve conduction velocity; SD: standard deviation; SNCV: sensory nerve conduction velocity </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Nerve conduction velocity measurements at 12 months' follow‐up (De Grandis 2002)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011265-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Nerve amplitude measurements at 12 months' follow‐up (De Grandis 2002)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Nerve amplitude measurements at 12 months' follow‐up (</b><a href="./references#CD011265-bbs2-0001" title="DeGrandisD , MinardiC . Acetyl‐L‐carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long‐term, randomised, double‐blind, placebo‐controlled study. Drugs in R&amp;D2002;3(4):223‐31. [PUBMED: 12455197] "><b>De Grandis 2002</b> </a><b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>ALC (&gt; 1500 mg/day)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar SN (µV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant (P = not available)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sural SN (µV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median SN (µV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peroneal MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.05</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ALC: acetyl‐L‐carnitine; MN: motor nerve; SD: standard deviation; SN: sensory nerve</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Nerve amplitude measurements at 12 months' follow‐up (De Grandis 2002)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011265-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Nerve conduction velocity measurements at 12 months' follow‐up (Li 2016)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Nerve conduction velocity measurements at 12 months' follow‐up (</b><a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] "><b>Li 2016</b> </a><b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>ALC (≤ 1500 mg/day)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change (m/s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change (m/s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median SNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar SNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sural SNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median MNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar MNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tibial MNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peroneal MNCV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ALC: acetyl‐L‐carnitine; MNCV: motor nerve conduction velocity; SD: standard deviation; SNCV: sensory nerve conduction velocity </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Nerve conduction velocity measurements at 12 months' follow‐up (Li 2016)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011265-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Nerve amplitude measurements at 12 months' follow‐up (Li 2016)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Nerve action potential amplitude measurements at 12 months' follow‐up (</b><a href="./references#CD011265-bbs2-0002" title="LiS , ChenX , LiQ , DuJ , LiuZ , PengY , et al. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomised, double‐blind, controlled trial. Journal of Diabetes Investigation2016;7(5):777‐85. [PUBMED: 27180954] "><b>Li 2016</b> </a><b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>ALC (≤ 1500 mg/day)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI or SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI or SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median SN (µV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.07 to 3.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 3.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar SN (µV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.30 to 1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 11.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sural SN (µV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.10 to 1.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.95 to 1.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 6.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulnar MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 2.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tibial MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.15 to 2.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.41 to 3.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peroneal MN (mV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.03 to 1.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 0.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ALC: acetyl‐L‐carnitine; CI: confidence interval; MN: motor nerve; SD: standard deviation; SN: sensory nerve </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Nerve amplitude measurements at 12 months' follow‐up (Li 2016)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/full#CD011265-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011265-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Acetyl‐L‐carnitine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain at 6 to 12 months' follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.16 [‐16.76, ‐1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ≤ 1500 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐8.00, 9.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 &gt; 1500 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.93 [‐19.16, ‐10.70]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Acetyl‐L‐carnitine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/references#CD011265-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011265-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Acetyl‐L‐carnitine versus methylcobalamin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Functional impairment and disability (change in Neurological Disability Scale) at 24 weeks' follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [‐0.15, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.68, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.22, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events leading to withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.22, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Symptom quality and severity (change in Neuropathy Symptom Score) at 24 weeks' follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐0.37, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Acetyl‐L‐carnitine versus methylcobalamin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011265.pub2/references#CD011265-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011265.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011265-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011265-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011265-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011265-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD011265-note-0004">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD011265-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011265-note-0006">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD011265-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD011265-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011265-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011265-note-0019">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011265\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011265\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011265\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011265\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011265\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011265.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011265.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011265.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011265.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011265.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728575395"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011265.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728575399"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011265.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec7d1680ff431',t:'MTc0MDcyODU3NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 